CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  1  Title  A Randomized, Double-Blind, Placebo -Controlled  Phase 2 Clinical Trial  
Comparing CB -839 in Combination with  Cabozantinib  (CB-Cabo) vs. 
Placebo with  Cabozantinib  (Pbo-Cabo) in Patients with Advanced or 
Metastatic Renal Cell Carcinoma (RCC)  
Protocol Number  CX-839-008 
IND Number  118397 
Sponsor Calithera Biosciences , Inc. 
343 Oyster Point Blvd, Suite 200  
South San Francisco, CA 94080  
Sponsor Contact    
 
Calithera Biosciences , Inc. 
343 Oyster Point Blvd, Suite 200  
South San Francisco, CA 94080  
Phone:  
EudraCT Number  2018-000363-91 
Date/Version  09 April 2020/Amendment 3.0 
 
 
Confidentiality Statement  
 
This document contains information that is confidential and proprietary to the Sponsor.  This information 
is being provided to you solely for the purpose of evaluating and/or conducting a clinical study for the 
Sponsor. You may disclose the contents of this document only to study  personnel under your supervision, 
institutional review boards (IRBs)/independent ethics committees (IECs), or duly authorized 
representatives of regulatory agencies for this purpose under the condition that they maintain 
confidentiality.  The contents of t his document may not be used in any other clinical study, disclosed to 
any other person or entity, and/or published without the prior written permission of the Sponsor.  The 
foregoing shall not apply to disclosure required by any regulations; however, you w ill give prompt notice 
to the Sponsor of any such disclosure.  All other nonpublic information provided by the Sponsor and any 
information that may be added to this document also is confidential and proprietary to the Sponsor and 
must be kept in confidence in the same manner as the contents of this document.  
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771

CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  2  1.0 TABLE OF CONTENTS  
1.0 TABLE OF CONTENTS  ................................ ................................ ................................ ..2 
2.0 LIST OF TABLES  ................................ ................................ ................................ .............6 
3.0 LIST OF FIGU RES ................................ ................................ ................................ ...........7 
4.0 CONTACTS  ................................ ................................ ................................ ....................... 8 
5.0 OBJECTIVES AND ENDPO INTS ................................ ................................ .................. 9 
6.0 SAMPLE SIZE  ................................ ................................ ................................ ................... 9 
7.0 STUDY DESIGN  ................................ ................................ ................................ ..............10 
7.1 Study Duration and End of Study Definition  ................................ ......................... 11 
8.0 INCLUSION/ EXCLUSION  CRITERIA  ................................ ................................ ......12 
8.1 Inclusion Criteria  ................................ ................................ ................................ ...12 
8.2 Exclusion Criteria  ................................ ................................ ................................ ..13 
9.0 BACKGROUND AND RATIO NALE ................................ ................................ ...........16 
9.1 Renal Cell Cancer  ................................ ................................ ................................ ..16 
9.2 Glutamin ase Inhibitor CB -839 ................................ ................................ ...............17 
9.3 Preclinical Activity of CB -839 ................................ ................................ ..............18 
9.4 Previous Human Experience with CB -839 ................................ ............................ 22 
9.4.1  Safety................................ ................................ ................................ .....23 
9.4.2  Efficacy of CB -839 plus Cabozantinib  ................................ ................. 26 
9.5 Rationale for CB -839 Dose Selection  ................................ ................................ ....27 
10.0  PROCEDURES  ................................ ................................ ................................ ................ 28 
10.1  Screening ................................ ................................ ................................ ................ 28 
10.1.1  Concomitant Treatment  ................................ ................................ .........28 
10.1.2  Screening Evaluation  ................................ ................................ ............30 
10.2  Randomization  ................................ ................................ ................................ .......30 
10.3  Study Treatment Procedures  ................................ ................................ .................. 31 
10.4 Long Term Follow Up  ................................ ................................ ........................... 32 
10.5  Screen Failures  ................................ ................................ ................................ .......32 
10.6  Procedure details  ................................ ................................ ................................ ....32 
10.6.1  Demographics, Medical, and Cancer History  ................................ .......33 
10.6.2  Physical Examination  ................................ ................................ ............33 
10.6.3  Vital Signs  ................................ ................................ ............................. 33 
10.6.4  Adverse Events ................................ ................................ ...................... 33 
10.6.5  Concomitant Medications  ................................ ................................ .....33 
10.6.6  Electrocardiograms  ................................ ................................ ...............34 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  3  10.6.7  Laboratory Assessments ................................ ................................ ........34 
10.6.8  Patient-Reported Quality of Life Assessment  ................................ .......34 
10.6.9  Tumor Assessments  ................................ ................................ ..............35 
10.6.10  Tumor Biopsies  ................................ ................................ ..................... 36 
10.6.10.1  Archival Tumor Biopsies  ................................ ............................... 36 
10.6.10.2  Optional Fresh Tumor Biopsies  ................................ ..................... 36 
10.6.11  Pharmacokinetic Samples  ................................ ................................ .....37 
10.6.12  Pregnancy, Contraception and Nursing/Breast -feeding ........................ 38 
10.6.12.1  Pregnancy Testing  ................................ ................................ ..........38 
10.6.12.2  Contraception  ................................ ................................ ................. 38 
10.6.12.3  Nursing/Breast -feeding ................................ ................................ ..40 
11.0  POTENTIAL TOXICITIES , DOSE MODIFICATION AND MANAGEMENT 
OF TOXICITIES  ................................ ................................ ................................ .............40 
11.1  Potential Toxicities  ................................ ................................ ................................ 40 
11.1.1  CB-839 ................................ ................................ ................................ ..40 
11.1.2  Cabozantinib  ................................ ................................ ......................... 40 
11.1.3  Dose Modification Guidelines  ................................ .............................. 41 
11.1.3.1  Study Drug Dose Levels  ................................ ................................ 41 
11.1.3.2  Study Drug Dose Modifications  ................................ .................... 41 
11.1.4  Cabozantinib Warnings, Precautions, and Guidelines for 
Management of Potential Advers e Events ................................ ............44 
11.1.4.1  Gastrointestinal Disorders  ................................ .............................. 44 
11.1.4.2  Hepatobiliary Disorders  ................................ ................................ .45 
11.1.4.3  Hematological Disorders  ................................ ............................... 46 
11.1.4.4  Fatigue, Anorexia, and Weight Loss  ................................ ..............46 
11.1.4.5  Skin Disorders  ................................ ................................ ................ 47 
11.1.4.6  Hypertension  ................................ ................................ .................. 48 
11.1.4.7  Thromboembolic Events  ................................ ................................ 49 
11.1.4.8  Proteinuria  ................................ ................................ ...................... 50 
11.1.4.9  Hypophosphatemia  ................................ ................................ ........51 
11.1.4.10 Thyroid Function Disorders  ................................ ........................... 51 
11.1.4.11  Hemorrhagic Events ................................ ................................ .......52 
11.1.4.12  GI Perforation/Fistula and Non -GI Fistula Formation ................... 52 
11.1.4.13  Osteonecrosis of the Jaw  ................................ ................................ 53 
11.2  Resumption of Study Treatment  ................................ ................................ ............54 
11.3  Discontinuation of Treatment  ................................ ................................ ................ 54 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  4  12.0  TEST ARTICLES/STUDY DRUGS ................................ ................................ ..............56 
12.1  Blinded Investigational Product  ................................ ................................ .............56 
12.2  Cabozantinib Study Drug  ................................ ................................ ....................... 57 
12.3  Missed or Vomited Doses  ................................ ................................ ...................... 57 
12.4  Packaging and Labeling  ................................ ................................ ......................... 57 
12.5  Storage and Stability  ................................ ................................ .............................. 57 
12.6  CB-839 Accountability, Reconciliation, and Return  ................................ .............58 
12.7  Test Article/Study Drug Compliance ................................ ................................ .....58 
13.0  MEASURES TO MINIMIZE /AVOID BIAS  ................................ ................................ 58 
14.0  STATISTICAL ANALYSIS  ................................ ................................ ........................... 58 
14.1  General Study Design  ................................ ................................ ............................ 59 
14.2  Independent Radiology Committee (IRC)  ................................ ............................. 59 
14.3  Independent Data Monitoring Committee  ................................ ............................. 59 
14.4  Study Steering Comm ittee ................................ ................................ ..................... 60 
14.5  Analysis Patient Sets  ................................ ................................ .............................. 60 
14.5.1  Efficacy Analysis Patient Set  ................................ ................................ 60 
14.5.2  Safety Analysis Set  ................................ ................................ ...............60 
14.6  Efficacy Analysis  ................................ ................................ ................................ ...60 
14.6.1  Primary Efficacy Endpoint: IRC -Adjudicated PFS  .............................. 60 
14.6.2  Secondary Efficacy Endpoints  ................................ .............................. 61 
14.6.3  Additional Endpoints  ................................ ................................ ............62 
14.6.4  Exploratory Analyses  ................................ ................................ ............63 
14.7  Safety Analysis  ................................ ................................ ................................ ......63 
14.8  Sample Size Estimation  ................................ ................................ ......................... 63 
15.0  ADVERSE EVENTS  ................................ ................................ ................................ .......64 
15.1  Definitions ................................ ................................ ................................ ..............64 
15.2  Recording and Reporting  ................................ ................................ ....................... 69 
15.3  Serious Adverse Event Reporting  ................................ ................................ ..........70 
16.0  STUDY SUSPENSION, TE RMINATION, AND COMPL ETION ............................. 71 
17.0  INFORMED CONSENT  ................................ ................................ ................................ .71 
18.0  PROTOCO L AMENDMENTS  ................................ ................................ ...................... 71 
19.0  QUALITY CONTROL AND ASSURANCE ................................ ................................ .72 
20.0  DIRECT ACCESS, DATA HANDLING, AND RECORD  KEEPING  ...................... 72 
20.1  Ethical Considerations  ................................ ................................ ........................... 72 
20.2  Investigator  ................................ ................................ ................................ ............72 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  5  20.3  Sponsor ................................ ................................ ................................ .................. 73 
20.4  Pre-Study Docum entation ................................ ................................ ...................... 73 
20.5  Records Retention  ................................ ................................ ................................ ..74 
21.0  PUBLICATION AND AUTH ORSHIP  ................................ ................................ ..........75 
22.0 LIST OF ABBREVIATION S ................................ ................................ ......................... 76 
23.0  REFERENCES  ................................ ................................ ................................ ................. 78 
ATTACHMENT 1: SCHEDU LE OF STUDY ASSESSME NTS ................................ ............80 
ATTACHMENT 2: CLINIC AL LABORATORY TESTS  ................................ ...................... 83 
ATTACHMENT 3: IMDC P ROGNOSTIC MODEL  ................................ .............................. 85 
ATTACHMENT 4: KARNOF SKY PERFORMANCE STAT US SCALE  ............................ 86 
ATTACHMENT 5: RECIST  CRITERIA VERSION 1. 1 ................................ ........................ 87 
ATTACHMENT 6: DRUG I NTERACTIONS  ................................ ................................ .........96 
ATTACHMENT 7: NCCN -FACIT MEASUREMENT SYS TEM (FKSI -19) 
QUESTIONNAIRE/ SCALE  ................................ ................................ .......................... 98 
ATTACHMENT 8: EUROQO L QUESTIONNAIRE ED -5D-5L (US ENGLISH 
SAMPLE VERSION)  ................................ ................................ ................................ ....100 
ATTACHMENT 9: SUMMAR Y OF CHANGES (AMENDMENT 3.0 VS. 2.0) ................. 102 
 
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  6  2.0 LIST OF TABLES  
Table 9.5 -1: CB-839 Related Adverse Events in ‚â• 5% of  Patients Treated with Monotherapy 
CB-839 on the BID Schedule on Study CX -839-001 ................................ ......23 
Table 9.5 -2: CX-839-001 CB-839 + Cabozantinib Treatment -Related Adverse Events1 .............25 
Table 11.1 -1: Dose Levels for CB -839/Placebo  ................................ ................................ ............41 
Table 11.1 -2: Dose Levels for Cabozantinib  ................................ ................................ ................. 41 
Table 11.1-3: Treatment Modifications Guidelines for Treatment -Related AEs  .......................... 43 
Table 11.1 -4: Management of Treatment -emergent PPE Syndrome  ................................ .............48 
Table 11.1 -5: Management of Treatment -emergent Hypertension ................................ ................ 49 
Table 11.1 -6: Management of Treatment -emergent Proteinuria  ................................ ................... 51 
Table A: Time Point Response: Patients with Targets (+/ - Non-Target) Disease  ......................... 95 
 
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  7  3.0 LIST OF FIGURES  
Figure 7.0 -1  Study Design Schema  ................................ ................................ ...................... 11 
Figure 9.3 -1 Antiproliferative and pro -apoptotic activity of CB -839 in kidney tumor 
cell lines in vitro. ................................ ................................ .............................. 19 
Figure 9.3 -2 Synergistic activity of CB -839 in combination with cabozantinib in the 
Caki-1 RCC cell line in vitro. ................................ ................................ ..........20 
Figure 9.3 -3 Inhibition of tumor growth by CB -839 in combination with other agents in 
the Caki-1 RCC cell line in vivo. ................................ ................................ .....21 
Figure 9.6 -4 Best tumor response for RCC patients receiving CB -839 + cabozantinib in 
Phase 1. ................................ ................................ ................................ ............27 
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  10  7.0 STUDY DESIGN  
Protocol CX-839-008 is a Phase 2 randomized, double -blind, placebo -controlled , multicenter 
study comparing two treatment reg imens for patients with ccRCC  (see Figure 7.0-1). Eligible 
patients will be randomized in a 1:1 ratio to the following study treatment arms:  
a) CB-Cabo ‚Äì CB-839 (800 mg twice daily [ BID]) + cabozantinib (60 mg  once daily  [QD])   
b) Pbo-Cabo ‚Äì Placebo + cabozantinib (60 mg QD)   
Randomization will be stratified by the following variables:  
a) Prior treatment with PD -1/PD-L1 inhibitor therapy  (yes vs. no) 
b) The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) 
Prognostic Risk Group  (favorable vs. intermediate  vs. poor; Attachment 3 ).  
The primary endpoint of this Phase 2 study is IRC-adjudicated PFS.  
Patients will receive study treatment determined by randomization in 28 -day cycles until disease 
progression per RECIST v.1.1 or unacceptable toxicity, whichever occurs first (see Section 11.3 
for further details). Patients will be followed for safet y for at least 28  days after the last dose of 
all study treatments (CB -839/placebo and cabozantinib), or until initiation of a new anticancer 
therapy, if earlier. Patients who discontinue study treatment for reasons other than disease 
progression by RECIST  v.1.1 or death will also continue to be followed by radiographic tumor 
imaging until documentation of radiographic progressive disease per RECIST  v.1.1, death, 
initiation of a new anticancer therapy, or withdrawal of consent as described in Section 10.6.9. 
Long-term follow up for survival will continue until death or withdrawal of consent for survival 
follow-up.  
A summary of the study design i s presented in  Figure 7.0-1. 
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
&% 3URWRFRO&;
$SULO$PHQGPHQW

&21),'(17,$/   
)LJXUH 6WXG\'HVLJQ6FKHPD 
6WXG\'XUDWLRQDQG(QGRI6WXG\'HILQLWLRQ
7KHVWXG\ZLOOHQUROOSDWLHQWVRYHUD SSUR[LPDWHO\PRQWKVZLW KDSSUR[LPDWHO\PRQWKVRI
DGGLWLRQDOIROORZXSHVWLPDWHGEHIRUH UHDFKLQJWKHHYHQWGULYHQ SULPDU\DQDO\VLVRI3)67KH
HQGRIVWXG\ZLOOEHGHILQHGE\WKHFRPSOHWLRQRIIROORZXSIRU WKHVHFRQGDU\HQGSRLQWRIRYHUDOO
VXUYLYDO7KHSURMHFWHGPD[LPXPWL PHUHTXLUHGIRURYHUDOOVXUYL YDOIROORZXSLV\HDUVDIWHUWKH
ODVWSDWLHQWLVHQUROOHG7KHWRW DOGXUDWLRQRIWKHVWXG\ZLOO EHDSSUR[LPDWHO\\HDUV
 
&;3URWRFRO$PHQGPHQW$SU_H70)9HUVLRQ_99 70)
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  12  8.0 INCLUSION / EXCLUSION  CRITERIA  
8.1 Inclusion  Criteria 
1. Informed Consent  
a. Ability to provide written informed consent in accordance with federal, local, and 
institutional guidelines  
2. Target Population  
a. Documented histological or cytological diagnosis of renal cell carcinoma with a 
clear-cell component 
b. Age ‚â• 18 years  
c. Karnofsky Performance Score ( KPS) ‚â• 70% (Attachment 4 ) 
d. Estimated Life Expectancy of at least 3 mo  
e. Measurable Disease per RECIST 1.1 as determined by the Investigator (see 
Attachment 5 ) 
f. One and not more than  two prior systemic lines of therapy (monotherapy or 
combination regimen) for advanced or metastatic RCC  
1) Must include either:  
i. one anti-angiogenic therapy ( any VEGF pathway -targeted agent, used 
either as monotherapy or a s a component of a combination regimen ) 
‚Äì OR ‚Äì  
ii. the combination regimen of nivolumab + ipilimumab  
2) Exposure to a prior treatment regimen for ‚â•4 weeks is considered a prior line 
of therapy , regardless of reason for its discontinuation  (exception: high -dose 
IL2 will count as prior therapy if >3 doses administered)  
i. 4 weeks will be counted from first to last dose for regimens that are 
intended to be administered on daily schedules (e.g., sunitinib, 
pazopanib) and from first dose to end of cycle length after last dose for 
regimens that are intended to be administered i n intervals of ‚â• 1 week 
(e.g., one treatment of a Q2W regimen counts as 2 weeks of therapy)  
3) Rechallenge with the same agent or regimen  will not be considered a new line 
of therapy , if the patient had not previously discontinued that agent or regimen 
because of disease progression   
4) Systemic adjuvant therapy is considered a prior line of therapy if the patient 
has disease recurrence on or within 1 year after the last dose  of adjuvant 
therapy  
g. The patient must have had radiographic evidence of disease progression on  or after 
the most recent systemic therapy and within 6 mo before randomization  
 
3. Laboratory Findings  
a. Serum creatinine ‚â§ 2.0 √ó upper limit of normal or calculated creatinine clearance  
(CCr) ‚â• 30 mL/min (‚â• 0.5 mL/sec) using the Cock croft-Gault equation:  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  13  CCr = {((l40 ‚Äì age) x actual body weight)/  (72 x S Cr)} x 0.85 (if female)   
b. Adequate hematological function, defined as absolute neutrophil count ‚â• 1,500/mm3, 
hemoglobin ‚â• 9.0 g/dL, and platelet count ‚â• 100,000/mm3. Transfusions and growth 
factors must not be used within 2 weeks prior to randomization  to meet these 
requirements.  
c. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3.0 √ó upper 
limit of normal.  
d. Total bilirubin ‚â§ 1.5 √ó the upper limit o f normal. For patients with Gilbert‚Äôs disease , 
‚â§ 3 mg/dL (‚â§ 51.3 Œºmol/L).  
e. Urine protein -to-creatinine ratio (UPCR) ‚â§ 1 mg/mg (‚â§ 113.2 mg/mmol) or  
24-hour urine protein < 1 g.  
4. Reproductive Status  
a. Female patients of childbearing potential must have a negativ e serum or urine 
pregnancy test and if sexually active must agree to contraceptive requirements 
outlined in  Section 10.6.12.2. Male patients who are s exually active with heterosexual 
partners of childbearing potential must agree to contraceptive requirements and sperm 
donation restrictions outlined in Section 10.6.12.2.  
5. Other Inclusion Criteria  
a. Recovery to baseline or ‚â§ Grade 1 CTCAE v.4.0 from toxicities related to any prior 
cancer therapy , unless after discussion with medical monitor adverse events (AE s) are 
deemed clinically non -significant and/or stable on supportive therapy.  
 
8.2 Exclusion Criteria  
1. Medical History  
a. Prior treatment with  cabozantinib (or other MET inhibitor) or CB-839 
b. Receipt of any anticancer therapy within the following windows before 
randomization : 
ÔÇ∑ Small molecule receptor tyrosine kinase inhibitor ( TKI) therapy (including 
investigational) within 2 weeks  or 5 half-lives, whichever is longer 
ÔÇ∑ Any type of anticancer antibody or cytotoxic chemotherapy within 
4 weeks 
ÔÇ∑ Radiation therapy for bone  metastasis within 2 weeks, any other external 
radiation therapy within 4 weeks , or systemic treatment with radionuclides 
within 6 weeks before randomization . Patients with clinically relevant 
ongoing complications (per investigator assessment) from prior radiation 
therapy are not eligible . 
ÔÇ∑ Other investigational therapy within 4 weeks or 5 half -lives, whichever is 
longer. 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  14  c. Patients with active and/or untreated  central nervous system ( CNS) cancer are not 
eligible.  Patients with treated brain metastases (1) m ust have documented 
radiographic stability of at least 4 weeks duration demonstrated on baseline 
contrast-enhanced CNS imaging (e.g., contrast-enhanced MRI of the brain) prior 
to randomization and (2) must be symptomatically stable and off of steroids (for 
the purpose of treating symptoms of brain metastases ) at least 2 weeks before 
randomization .  
d. Any other current or previous malignancy within the past three years except :  
ÔÇ∑ Adequately treated basal cell or squamous cell skin cancer,  
ÔÇ∑ Carcinoma in situ of the cervix,  
ÔÇ∑ Other neoplasm that, in the opinion of the Principal Investigator and with 
the agreement of the Medical Monitor, will not interfere with study -
specific endpoints  
e. Previously identified allergy or hypersensitivity to componen ts of the study 
treatment formulations  (Note: patients with rare hereditary problems of galactose 
intolerance, the Lapp lactase deficiency , or glucose -galactose malabsorption 
should not take cabozantinib  and are also excluded). 
f. Corrected QT interval (QTc) > 500 msec within 1 mo before randomization  
ÔÇ∑ Cabozantinib should be used with caution in patients with a history of QT 
interval prolongation, patients who are taking antiarrhythmics, or patients 
with clinically relevant pre -existing cardiac disease, bradyca rdia, or 
electrolyte disturbances . 
 
2. Concurrent Conditions  
a. Unable to receive oral medications  or any condition  that may prevent adequate 
absorption of oral study medication including refractory nausea and vomiting, 
uncontrolled diarrhea, malabsorption, small bowel resection or gastric bypass 
surgery, use of feeding tubes  
b. Major surgery (e .g., GI surgery) within 6 weeks before first dose of study 
treatment  or incomplete wound healing from any prior surgery.  Patients with 
clinically relevant ongoing complications (per investigator assessment) from prior 
surgery are not eligible.  
c. The patient has uncontrolled, significa nt current or recent illness including, but 
not limited to, the following conditions:  
ÔÇ∑ Cardiovascular disorders:  
i. Symptomatic congestive heart failure, unstable angina pectoris, 
serious cardiac arrhythmias  
ii. Uncontrolled hypertension defined as sustained BP >  150 mm Hg 
systolic or > 100 mm Hg diastolic despite optimal antihypertensive 
treatment  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  15  ÔÇ∑ Stroke (including TIA), myocardial infarction, or other ischemic event  
within 6 mo before randomization  
ÔÇ∑ Gastrointestinal (GI) disorders including those associated with a high risk 
of perforation or fistula formation:  
i. Tumors invading the GI  tract, active peptic ulcer disease, 
inflammatory bowel disease, diverticulitis, cholecystitis, 
symptomatic cholangitis or appendicitis, acute pancreatitis or acute 
obstruction of the p ancreatic or biliary duct, or gastric outlet 
obstruction  
ii. Abdominal fistula, gastrointestinal perforation, bowel obstruction, 
or intraabdominal abscess within 6 mo before randomization  
iii. Complete healing of an intra -abdominal abscess must be confirmed 
before randomization  
ÔÇ∑ Clinically significant hematuria, hematemesis, or hemoptysis of >  0.5 
teaspoon (2.5 m L) of red blood, or other history of significant bleeding 
within 3 mo before randomization  
ÔÇ∑ Moderate to severe hepatic impairment (Child -Pugh B or C)  
ÔÇ∑ Lesions invading major pulmonary blood vessels  
d. Known active infection with HIV or Hepatitis B or C virus  
e. Anticoagulation with warfarin at therapeutic doses is prohibited.   
ÔÇ∑ Note: Anticoagulation with therapeutic doses of low molecular weight 
heparin (LMWH), direct thrombin  inhibitors, factor Xa inhibitors, and 
platelet inhibitors (e.g.,  clopidogrel ) is allowed in patients without brain 
metastases  who are on stable doses for at least 4 weeks before 
randomization and have had no complications from the anticoagu lation 
regimen.   
ÔÇ∑ Low-dose aspirin for cardioprotection, and low -dose (prophylactic) low 
molecular weight heparin ( LMWH) are permitted .  
f. Inability to discontinue  proton pump inhibitor use before randomization  
g. Any condition including social, psychiatric or medical (including uncontrolled 
significant concurrent illness) that in the opinion of the Investigator could 
interfere with treatment or protocol -related procedures  
h. Patients who are pregnant or lactating  
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  16  PROTOCOL DETAILS  
9.0 BACKGROUND AND RATIO NALE 
9.1 Renal Cell Cancer  
Renal cell carcinoma represents approximately 3% of malig nancies, with current worldwide 
diagnoses and deaths of approximately 295,000 and 134 ,000 respectively ( Hsieh 2017). 
Approximately a third of patients diagnosed with RCC have curative partial or complete 
nephrectomy, a third of patients experience disease recurrence following nephrectomy, and a 
third of pati ents are diagnosed with de novo metastatic disease. Treatment of metastatic RCC 
(mRCC) is based on disease histology, patient overall health and performance status, and the 
number and type of prior systemic th erapies. First -line patients with clear -cell mRCC typically 
receive vascular en dothelial growth factor (VEGF) -targeted therapy, most commonly the TKIs 
sunitinib or pazopanib, although the anti -VEGF antibody bevacizuma b in combination with 
low-dose gamma interferon is also an option. After failure of first-line anti-angiogenesis therapy, 
patients generally receive the anti -PD-1 antibody nivolumab or one of several TKIs (most 
commonly cabozantinib or axitinib). Pat ients may receive the mTOR inhibitor everolimus in 
second line, however this agent is now pr imarily used in the third-line and later setting s. 
Despite the availability of multiple approved therapies for the treatm ent of mRCC in first and 
second line, these agents rep resent a limited number of anti cancer mec hanisms: angiogenesis 
targeting agents (TKIs or antibodies) or immune modulating agents (PD -1 inhibitor or 
cytokines). Most importantly, from the standpoint of unmet medical need, very few pat ients with 
mRCC are cured by therapy, and a substantial number receive little benefi t from treatment. I n the 
second-line setting, based on pivotal studies that lead to marketing approvals in the US and 
Europe, cabozantinib has a n ORR of 17%, median PFS of 7.4  mo and median  OS of 21.4 mo 
(Choueiri 2016), and nivolumab has an ORR of 25% , median PFS of 4.6  mo, and median OS of 
25 mo (Motzer 2015). Therefore, there is significant need for improved efficacy in the  treatment 
of mRCC  and for the development of therapies with novel and distinct mechanisms of action.  
Of importance for the first-line treatment of patients with mRCC, and therefore of importance for 
the design of second -line clinical studies, data were recently presented at the September 2017 
European Society of Medical Oncology Congress in Ma drid (Escudier 2017). The Phase  3 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  17  randomized CheckMate 214 study compared the combination re gimen of nivolumab + 
ipilimumab  to the standard -of-care regimen of sunitinib for the first-line treatment of patie nts 
with mRCC. In the primary analysis of  patients with intermediate and poor risk disease, the 
study demonstr ated a 37% reduction in risk of death (hazard ratio 0.63, p<0.0001) for the 
experimental compar ed to control arm as well as an increased ORR (42% vs. 27%), an increased  
complete response (CR) rate (9% vs. 1%) , and a 3.2-mo improvement in median PFS  (p<0.03). 
In the intent -to-treat (ITT) analysis of all 1096  randomized patients , including favorable -risk 
patients, the median OS remained significantly improved for the nivolumab + ipilimumab 
combination compared to sunitinib, with a 32% reduction in risk of death (hazard ratio 0.68, 
p<0.0003 ). In addition, the exploratory endpoint of health -related QoL favored the nivolumab + 
ipilimumab arm over the suni tinib arm. Although  these data are not yet reflected in regulatory 
approval, the y are considered to represent a ‚Äúparadigm shift‚Äù in the first -line treatment of mRCC 
and should be consi dered in the design of second -line mRCC trials.   
In addition, the Phase  2 randomized trial of cabozantinib compared with sunitinib in the first -line 
treatment of patients with mRCC demonstrated a 52% reduction in the risk of progression or 
death in patients with intermediate and poor risk disease (adjusted hazard ratio 0. 48, p=0.0008; 
median PFS per IRC 8.6 mo vs. 5.3 mo) and increased ORR ( 20% vs. 9%) in favor of 
cabozantinib ( Choueiri 2018). These data support the benefit of cabozantinib in patients without 
prior antiangiogenic therapy and the consideration that second -line mRCC trials including 
cabozantinib should not be restricted to patients with prior antiangiogenic therapy.  
9.2 Glutaminase Inhibitor CB-839 
CB-839 is a potent and selective reversible inhibitor of glutaminase activity ( Gross 2014). It is an 
allosteric and noncompetitive inhibitor of glutaminase (GLS gene product), but does not inhibit 
the liver isoform, glutaminase -2 (GLS2 gene product). (Throughout this document, g lutaminase 
refers to the GLS gene products only. ) Incubation of recombinant human glutaminase with 
CB-839 results in time -dependent and slowly reversible inhibition of glutaminase activity (IC 50 = 
34 nM with 1 hr pre -incubation).  Glutaminase inhibition is associated with antiproliferative 
activity in a wide range of human tumor cell lines in vitro and in vivo when implanted in 
immunocompromised mice.  The effect of glutaminase inhibition on tumor cell growth closely 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  18  correlates with a similar response to with drawal of glutamine; the absolute requirement of most 
tumor cells for glutamine involves the production of glutamate by glutaminase.  
CB-839 is being developed for the treatment of RCC and other malignancies . Single-agent 
antitumor activity of CB -839 has been demonstrated in vitro in multiple RCC cell lines , and 
CB-839 has been shown to have antitumor activity in animal studies  as a single agent and in 
combination  with drugs such as everolimus, cabozantinib, and sunitinib, where additive or 
synergistic activity in immunocompromised mice was observed. CB-839 was also shown to 
enhance the activity of anti-PD-1 and anti -PD-L1 immune checkpoint inhibitor s, where there 
was a significant improvement in the incidence of syng eneic tumor regression in immuno -
competent mice.  The mechanism of action of CB -839 may involve a combination of a) direct 
anti-tumor activity resulting from blockade of glutamine utilization and b) indirect stimulation of 
anti-tumor immune response due to the accumulation of glutamine in the tumor 
microenvironment.  
9.3 Preclinical Activity of CB -839  
CB-839 has antiproliferative activity across a wide range of tumor cell types including solid 
tumors (ccRCC, non-small cell lung cancer , triple negative breast cancer [TNBC], etc.) and 
hematological tumors (multiple myeloma, acute myeloid leukemia , diffuse large B -cell 
lymphoma) , with IC 50 values ranging from 1 to 100  nM. When CB -839 was administered twice 
daily to immunocompromised mice be aring a variety of human tumor xenografts, including 
ccRCC and TNBC, a reduction of tumor growth rate was observed.  CB-839 administration was 
well-tolerated up to 400  mg/kg BID and resulted in substantial inhibition of tumor growth.   
Incubation of cell lin es with CB -839 leads to inhibition of glutaminase with a consequent 
increase in the cellular pools of the substrate glutamine and decrease in the product glutamate 
and metabolites derived from glutamate.  Similar increases in glutamine and decreases in 
glutamate are observed in xenografted tumors from animals treated with CB -839. In the TNBC 
cell line HCC1806, inhibition of proliferation and metabolite changes were observed at similar 
CB-839 concentrations ( Gross 2014), consistent with an on -target mechanism of action.  
Importantly, the antiproliferative activity of CB -839 across cancer cell lines from multiple 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  19  histological types (including ccRCC) is associated with inhibition of mTOR signaling, likely 
resulting from depletion of intracellular pools of nutrient amino acids.  
The antiproliferative and pro -apoptotic activity of CB -839 has been characterized in a panel of  
kidney cancer cell lines ( Figure 9.3-1). Clear-cell RCC cell lines appear to be more sensitive to 
the effects of CB -839 as compared with other kidney cancer cell lines.  
 
 
Figure 9.3-1 Antiproliferative and pro -apoptotic activity of CB -839 in kidney tumor cell lines in 
vitro.  
Kidney cancer cells were incubated with 1 ¬µM CB -839 for 72 hr.  Cell growth or cell loss 
(death) relative to vehicle control sam ples are shown for each cell line on the y -axis.  
 
The combination of CB -839 with the TKI cabozantinib was evaluated in vitro and included 
assessments of a) anti -proliferative activity, b) inhibition of signal transduction via the Ras/Raf 
pathway, and c) i nhibition of oxidative phosphorylation as measured by reduced oxygen 
consumption . The activity of each drug individually and when given in combination is shown in 
Figure 9.3-2.  
CB-839 has strong synergistic activity in combination with cabozantin ib with respect to the 
inhibition of cellular proliferation ( Figure 9.3-2, Panel A).  (Note: Combination Index values of 
1.0 indicate additivity , and values significantly lower than 1.0 indicate synergy in this assay  
[Chou 1984]). This may be, in part, due to the enhanced inhibition of VEGF  signaling achieved 
with the combination ( Figure 9.3-2, Panel B). Furthermore, there is a greater reduction in aerobic 
mitochondrial respiration (oxygen consumption) by the combination  than either agent alone 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
&% 3URWRFRO&;
$SULO$PHQGPHQW

&21),'(17,$/   )LJXUH 3DQHO&OLNHO\GXHWRWKHGXDOPHWDEROLFLQKLELWLRQRIJOXFR VHDQGJOXWDPLQH
XWLOL]DWLRQSDWKZD\V

)LJXUH 6\QHUJLVWLF DFWLYLW\RI&%LQFRPELQDWLRQZLWKFDER]DQWLQLELQWKH&DNL 
5&&FHOOOLQH LQYLWUR
$$QWLSUROLIHUDWLYHDFWLYLW \LQFHOOVWUHDWHGZLWKDGRVHUDQJ HRI&%DORQH
FDER]DQWLQLEDORQHRU&%FDER]DQWLQLE)ROORZLQJDKU LQFXEDWLRQZLWK
FRPSRXQGVFHOOYLDELOLW\ZDVPH DVXUHGDQGQRUPDOL]HGWRWKH'0 62WUHDWHG
FRQWURO5HSUHVHQWDWLYHGRVHUHV SRQVHSURILOHVDQGDYHUDJHFDOF XODWHG&KRX7DODOD\
&RPELQDWLRQ,QGH[YDOXHVIURPPXOWLS OHH[SHULPHQWVDUHVKRZQ% ,QKLELWLRQRI
VLJQDOLQJLQWKH3,.P725DQG5DV 5DISDWKZD\VLVPHDVXUHGE\ WKH
SKRVSKRU\ODWLRQRI$.7DQG(5.UHVSHFWLYHO\LQ:HVWHUQEORWV &7KHLQKLELWLRQ
RIR[LGDWLYHSKRVSKRU\ODWLRQLVPHDVXUHGE\DUHGXFHGR[\JHQFR QVXPSWLRQUDWH
&%SRWHQWLDWHVWKHDFWLYLW\RIFD ER]DQWLQLEDVZHOODVRWK HUDJHQWVWKDWEORFNWKH5DV5DI
DQG3,.P725SDWKZD\VLQFF5&&FHOOOLQHVHJWKHP725LQKL ELWRUHYHUROLPXVDQGWKH
7.,VXQLWLQLELQWKH&DNL FF5&&FHOOOLQHLQLPPXQRFRPSURPL VHGPLFH)LJXUH (DFK
DJHQWDVPRQRWKHUDS\HOLFLWHGPRGHVWWXPRUJURZWKLQKLELWLRQZ KLFKZDVVXEVWDQWLDOO\
LQFUHDVHGZKHQGRVHGLQFRPELQDWLRQ:KH QFDER]DQWLQLEZDVDGPL QLVWHUHGDWDORZGRVH
PJNJ4'V\QHUJLVWLFDFWLYLW\ZDVREVHUYHG )LJXUH 3DQHO$:KHQJLYHQDWDKLJK
GRVHPJNJ4'ERWKFDER]D QWLQLEDORQHDQGFDER]DQWLQLELQ FRPELQDWLRQZLWK&%
UHVXOWHGLQFRPSOHWHLQKLELWLRQRIWXPRUJURZ WK+RZHYHUZKHQ GRVLQJZDVGLVFRQWLQXHGLQ
WKHVHDQLPDOVUHFRYHU\R IWXPRUJURZWKZDVPRUHUDSLGLQDQLPD OVWUHDWHGZLWKVLQJOHDJHQW
&;3URWRFRO$PHQGPHQW$SU_H70)9HUVLRQ_99 70)
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  22  9.4 Previous Human Experience  with CB-839 
Three separate Phase 1 studies were initiated in February 2014 to evaluate the safety, 
pharmacokinetics, and pharmacodynamics of orally administered  CB-839 either  as a single agent 
or in combination with appro ved agents in patients with solid tumors (CX -839-001), multiple 
myeloma and Non-Hodgkin‚Äôs Lymphoma  (CX-839-002), or acute leukemia (CX -839-003). CX-
839-001 enrolled RCC patients for treatment with CB-839 + cabozantinib and CB-839 + 
everolimus , as well as  TNBC patients for treatment with CB-839 + paclitaxel . In addition, the 
combination of CB -839 with nivo lumab is being evaluated in the Phase 1/2 study , CX-839-004. 
During dose escalation in all three Phase 1 studies, single -agent CB-839 was administered 
initially three times daily (TID) without meals and was later changed to a BID schedule with 
breakfast and dinner.   
As of data cuts on 28 September 2017, a total of 102 patients received 600, 800, or 1000 mg BID 
CB-839 as a single agent; an additional 59 pat ients received single -agent CB-839 dosed on the 
TID schedule ranging from 100 to 1000 mg TID.  More than 190 patients have received CB -839 
at doses ranging from 400 to 800 mg BID in combination with cabozantinib, erlotinib, 
everolimus, paclitaxel, nivolumab, dexamethasone, pomalidomide, or azacitidine . 
In pharmacokinetic studies, the half -life of CB -839 was approximately 4 hr. A dose-related 
increase in exposure was observed  over doses ranging from 100 to 600 mg ; exposures for  
600 mg and 800 mg doses were similar albeit with significant  interpatient variability.  In 
pharmacodynamic studies, r obust inhibition of glutaminase  was demonstrated in platelets  at 
exposures  maintained in most BID-dosed patients at 600 mg and 800 mg inter-dose trough s, with 
the 800 mg dose in particular showing ‚â• 90% target inhibition . Patient tumor biopsies also 
demonstrated robust glutaminase inhibition  (> 75% for most patients).   
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  23  9.4.1 Safety 
Please refer to the current CB-839 Investigator‚Äôs Brochure for the most recent saf ety information 
for CB-839 monotherapy and CB -839 in combination regimens.  
CB-839 Monotherapy  
Treatment -related AEs for patients  enrolled on Study CX -839-001 who received monotherapy 
with CB-839 on the BID fed regimen are presented in Table 9.5-1. Of 88 safety -evaluable 
patients, 61 (69.3%) experienced AEs that were considered possibly or probably related to 
CB-839. The most frequent CB -839-related AEs were fatigue, gastrointestinal AE s (e.g., nausea, 
decreased appetite, and vomiting), liver function test (LFT) elevations (e.g., AST, ALT), and 
photophobia.  These AEs were typically mild to moderate in intensity (Gr ade 1/2), reversible, and 
manageable without dose interruption or modifica tion.  
The most frequent Gr ade 3 AEs were elevations in LFTs, including AST, ALT, and alkaline 
phosphatase.  Gamma-glutamyltransferase  elevations were also noted but are of unclear clinical 
significance.  The frequency of Gr ade 3 elevations in LFTs was limit ed, with 2 of 88 patients 
experiencing a treatment -related Gr ade 3 AST or ALT elevation.  One Grade 3 AE of anemia was 
also considered to be possibly related to CB -839 (not shown).  There have been no reported 
Grade 4 or Grade  5 treatment -related adverse eve nts.  
Table 9.5-1: CB-839 Related Adverse Events in ‚â• 5% of Patients Treated with 
Monotherapy CB -839 on the BID Schedule on Study CX -839-001 
BID fed - Monotherapy (N=88)  
MedDRA Preferred Term  Number (%) of patients 
All Grades  Grade 3 
Patients with Any CB -839-Related AE  61 (69.3) 3 (3.4) 
Fatigue 22 (25.0) 0 
Nausea 20 (22.7) 0 
Alanine aminotransferase increased  13 (14.8) 2 (2.3) 
Photophobia  12 (13.6) 0 
Aspartate aminotransferase increased  10 (11.4) 1 (1.1) 
Decreased appetite  7 (8.0) 0 
Gamma-glutamyltransferase increased  7 (8.0) 2 (2.3) 
Blood alkaline phosphatase increased  6 (6.8) 1 (1.1) 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  24  Vomiting  5 (5.7) 0 
23July2017 data cut  
Photophobia and related ocular toxicities (e.g., photopsia) have been identified as 
CB-839-related events.  In all but one case, these events have been Grade 1 and without impact 
on patients‚Äô daily lives.  One photophobia event was characterized as Grade 2. These events 
appear to occur around C max (1-4 hr after dosing) and res olve over a few hours.  These events 
have been reported to become less frequent over extended dosing.  Note: Photophobia/photopsia 
should be carefully distinguished from ‚Äúphotosensitivity‚Äù .  ‚ÄúPhotosensitivity‚Äù, which refers to an 
adverse event of the skin  such as an unexpected sunburn or dermatitis on sun-exposed skin , has 
not been observed with CB -839 monotherapy  or in combination with cabozantinib . 
 
CB-839 in Combination  
CB-839 has been combined in Phase 1 studies with standard of care therapies in a numbe r of 
different solid tumors, including everolimus (N = 27), cabozantinib (N = 12), paclitaxel (N  = 49), 
nivolumab (N = 82), and erlotinib (N = 1).  In all cases thus far, the Adverse Event profile of 
CB-839 administered at 600 -800 mg BID together with the full dose of each partner agent has 
been similar to those previously reported for each agent alone. Additional  details are  available in 
the Investigator‚Äôs Brochure.   
CB-839 + Cabozantinib  
Based on the da ta cut on 23 October 2018 for patients enrolled on the phase 1 Study CX -839-
001, treatment-related AEs reported for ‚â•2 patients among 13 patients receiving CB -839 (6 at 
600 mg BID and 7 at 800 mg BID) with cabozantinib 60 mg QD are presented in  Table 9.5-2. 
The combination was well tolerated at the 600 mg BID dose and the 800 mg BID dose of 
CB-839. The most frequent ly reported  treatment -related AEs (assessed as possibly or probably 
related to ei ther study drug) were diarrhea, elevations in alanine amino transferase and aspartate 
amino transferase, decreased appetite , nausea, fatigue, and rash . Grade 3 or Grade  4 events were 
one event each of Grade  3 diarrhea, Grade  3 hallucination, Grade  3 hypertension, and Grade  4 
decreased platelet count, the last  of which was the sole dose limiting toxicity (DLT) reported 
during dose escalation (600  mg BID CB -839 cohort).  As with other CB-839 combination 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  25  regimens, the recommended Phase  2 dose (RP2D) of CB-839 in combination with full dose 
cabozantinib was determined to be 800  mg BID. (See Section 11.1.2 for information about 
cabozantinib monotherapy safe ty). 
Table 9.5-2: CX-839-001 CB-839 + Cabozantinib Treatment -Related Adverse Events1 
CB-839 600 mg  BID or 800 mg BID  + Cabozantinib 60 mg (N= 13) 
MedDRA Preferred Term  Number (%) of patients  
All Grades  ‚â•Grade 32 
Patients with a ny treatment -related AEs1  13 (100.0)  5 ( 38.5) 
DIARRHOEA   8 ( 61.5)  1 ( 7.7) 
ALANINE AMINOTRANSFERASE INCREASED   6 ( 46.2)  0 
DECREASED APPETITE   6 ( 46.2)  0 
ASPARTATE AMINOTRANSFERASE INCREASED   5 ( 38.5)  0 
FATIGUE  5 ( 38.5)  0 
NAUSEA   4 ( 30.8)  0 
RASH 4 ( 30.8)  0 
MUCOSAL INFLAMMATION   3 ( 23.1)  0 
PROTEINURIA   3 ( 23.1)  0 
VOMITING   3 ( 23.1)  0 
WEIGHT DECREASED  3 ( 23.1)  0 
DEHYDRATION   2 ( 15.4)  0 
DYSGEUSIA  2 ( 15.4)  0 
HYPERTENSION  2 ( 15.4) 1 ( 7.7) 
MUSCLE SPASMS  2 ( 15.4) 0 
PLATELET COUNT DECREASED  2 ( 15.4)  1 ( 7.7) 
PRURITUS  2 ( 15.4)  0 
STOMATITIS  2 ( 15.4) 0 
1 Adverse events assessed by investigator as possibly or probably related to either CB -839, cabozantinib or  
  both; preferred terms reported in ‚â•2  patients. 
2 Additional Grade 3 adverse event of hallucination reported in 1 patient.  
CB-839 + Everolimus  
As discussed in Section 9.3, the combinations of CB-839 with everolimus and with cabozantinib 
share a common mechanism of action.  Inhibitors of the Ras/Raf and PI3K/mTOR pathways 
inhibit glucose utilization while CB -839 blocks glutamine utilization.  The safety profile of these 
two combinations together wi th the preclinical data strongly suggest  that this is a tumor -specific 
mechanism with little impact on normal cells and tissues.  The combination of CB -839 with 
everolimu s has been well tolerated to date. Of 27 patients who received CB -839 (400 mg, 
600 mg or 800 mg BID with food) in combination with everolimus, the most frequent AEs were 
anemia, decreased appetite, creatinine increase , fatigue, cough, diarrhea,  nausea, and 
hyperglycemia . Grade 3 treatment-related adverse events were few in number , with the most 
common being decreased appetite, anemia, fatigue, and mucosal inflammation, and there have 
been no related Grade 4 events.   One event of Grade 3 pruritic rash occurred at the CB-839 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  26  400 mg BID dose leve l and was considered a DLT . The rash was considered related to 
everolimus and resolved upon a dose reduction of everolimus (CB -839 continued at full dose).    
9.4.2 Efficacy of CB -839 plus Cabozantinib   
Please refer  to the current CB-839 Investigator‚Äôs Brochure for the most recent efficacy 
information for CB -839 monotherapy and CB -839 in combination regimens.  
As of 24 September  2018, 13 patients have been enrolled  and treated on Study CX -839-001, with 
the combination of cabozantinib and CB-839 (6 pts at 600 mg BID and 7 pts at 800 mg BID).  
Enrolled patients had  received a median of 3 prior lines of therapy  (range 0-7, including 1  patient 
with papillary RCC who had not received prior therapy) . Among twelve response-evaluable 
patients treated with the combination , all have received clinical benefit , including 12 of 
12 patients with tumor shrinkage , and among evaluable clear cell RCC patients 5 of 10  (50%) 
had a partial response ( PR) by RECIST 1.1.   
A waterfall plot of tumor response  is shown in Figure 9.6-4.
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 28  inhibition < 90%. In aggregate , these data support the risk:benefit ratio of the 800 mg BID 
CB-839 dose level  when given alone or in the presence of a variety of standard of care agents . 
10.0 PROCEDURES  
This section describes evaluations to be performed during the different periods  of this study.  All 
patients must sign an IRB/ IEC-approved informed consent  prior to starting any protocol -specific 
procedures, including screening procedures ; however, evaluations performed as part of routine 
care prior to informed consent can be utilized  as screening evaluations if permitted by the site‚Äôs 
IRB/IEC policies.  During the consent process, the person obtaining consent must inform the 
patient of all elements of informed consent.  
10.1 Screening  
An IRB/EC -approved Informed Consent Form (ICF) must be s igned and dated before any study -
specific (i.e., non -standard of care) screening procedures are performed. The ICF must be signed 
and dated ‚â§42  days prior to randomization.  
To determine a patient‚Äôs eligibility , patients will undergo required screening eva luations as 
outlined in Attachment 1 . Required screening assessments must be completed within 28  days 
prior to randomization, unless otherwise indicated. Patients must meet all inclusion criteria and 
none of the exclusion criteria in order to be deemed eligible and randomized into the study.  The 
investigator is responsible for reviewing all screening data to confirm patient eligibility; a 
Medical Monitor representing the Sponsor will review a brief eligibility che cklist with entries of 
select screening data to approve patient randomization.  
10.1.1 Concomitant Treatment  
Concomitant treatment is permitted if the medication is not expected to interfere with the 
evaluation of safety or efficacy of the study drug s.  
Non-protocol systemic anti cancer treatment , surgical resection of lesions, use of investigational 
therapeutic agents other than the study drugs , and palliative radiation to non -bone tumors are  
NOT permitted while the patient is on study.  In general, p alliative (limited field) radiation for 
bone metastasis pain should not be performed while on study.  If palliative radiation to a bone 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 29  lesion is deemed clinically unavoidable  for symptoms that in the opinion of the investigator are 
not due to progressive disease, the inv estigator must seek Sponsor approval prior to the 
procedure.  Note that t hese patients may be considered non-evaluable or assigned a n early 
censoring date or progression date  at the date of first such therapy . Initiation of therapeutic 
anticoagulation is allowed on study , as clinically indicated,  in consultation with the Sponsor‚Äôs 
medical monitor.  Chronic use of immunosuppressive medication during study treatment is 
prohibited with the exceptions of inhaled or topical cort icosteroids and  corticosteroids wi th a 
daily dosage equivalent of ‚â§  10 mg prednisone .  
CB-839 is metabolized by human hepatocytes primarily through amide hydrolysis.  CB-839 does 
not appear to induce CY P drug-metabolizing enzymes and only weakly inhibits CYP2C9 ( ~40-
50% inhibition at 5¬µM ) in vitro. Although CB -839 is not expected to inhibit CYP2C9 at the 
exposure levels planned, caution is warranted when administering CB -839 to patients taking 
drugs that are highly dependent on CYP2C9 for metabolism and have a narrow therapeutic 
index. A list of medications that are CYP2C9 substrates is provided in Attachment  6. 
Preliminar y PK data generated in single-agent Phase 1 studies indicate that concomitant use of 
proton pump inhibitors (PPIs) may reduce absorption of CB-839, resulting in decreased systemic 
exposure. Discontinuation of PPIs is re quired for patients on study . Alternative antacids such as 
H2 blockers (e. g., ranitidine, famotidine ) and buffering agents (e.g., sodium bicarbonate , calcium 
carbonate , and sucr alfate) may be substituted for PPIs ; however to aid absorption, it is 
recommended to plan CB-839 dosing at the time of minimal exposure to the antacid (e.g.,  10 hr 
after last dose of H2 blockers , or 2 hr before each dose of H2 blocker if administered BID).  
Please consult the medical monitor if a patient experiences significant difficulties with gastric 
symptoms during the study  and requires a PPI based on the investigator‚Äôs assessment.  
Cabozantinib is a substrate of CYP3A4, and concomitant use of strong inhibitors or inducers of 
CYP3A4 may affect cabozantinib exposure. See Attachment  6 for a summary of related data and 
examples of strong CYP3A4 inhibitors or inducers . Refer to the most current cabozantinib 
prescribing information for additional details and guidance . 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 30  10.1.2 Screening Evaluation  
Procedures listed below that are performed as part o f the normal standard of care and within the 
required screening windows (‚â§ 28 days prior to randomization, unless otherwise specified) may 
be used for screening purposes : 
ÔÇ∑ Demographic information including date of birth, sex , race, and ethnic origin   
ÔÇ∑ Medical history including review of prior cancer treatments , procedure s, and surgeries  
ÔÇ∑ Review of concomitant medications  
ÔÇ∑ Karnofsky  performance evaluation  
ÔÇ∑ Complete  physical examination including weight and height 
ÔÇ∑ Vital signs  
ÔÇ∑ Standard 12 -lead ECG   
ÔÇ∑ Clinical laboratory evaluation s; see Attachment  2. 
ÔÇ∑ Serum or u rine pregnancy test  for females of child -bearing potential   
ÔÇ∑ Radiographic evaluation of tumor burden  meeting requirements described in 
Section 10.6.9  
ÔÇ∑ Brain MRI if history of brain metastases  or suggestive symptoms  
ÔÇ∑ Bone scan if history of bone metastases  or suggestive symptoms  
10.2 Randomization  
Patients eligible after completing all screening evaluations will be randomly assigned by an 
interactive response technology (IRT) system in a 1:1 ratio to receive CB-Cabo or Pbo-Cabo. 
Randomization will be stratified by the following factors:  
ÔÇ∑ Prior treatment with PD -1/PD-L1 inhibitor therapy: Yes vs. No  
ÔÇ∑ IMDC Prognostic Risk Group : favorable vs. intermediate  vs. poor (Attachment 3 ) 
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 31  Randomization should occur as close as possible to the planned start of treatment (i .e., within 
24 hr if practicable but no more than 3  days). Patients are defined as enrolled in the study if 
randomized.   
Crossover between treatment arms will not be allowed.  
10.3 Study Treatment  Procedures  
For the complete list of schedules of procedures, please refer to the Schedule of Assessments in 
Attachment 1 .  
While the patient is receiving study treatment, the patient‚Äôs clinical status should be evaluated at 
each clinic visit to confirm that the patient is suitable for continuing study treatment and to make 
timely decisions regarding the interruption or restarting of study treatment.  
Assessments are based on 28 -day cycles . Radiographic evaluation of tumor burden  and QoL 
questionnaires  will be performed as scheduled relative to the date of Cycle 1 Day 1 (C1D1) 
regardless of study treatment holds or delays . Additional assessments may occur , as clinically 
indicated, during unscheduled  visits.  
After randomization, c linic visits for safety evaluations will occur Day 1 of every cycle  
(approximately every 4  weeks) for the first 1 2 cycles. Starting with C ycle 13, safety evalua tions 
will occur every 3  cycles (approximately every 12 weeks). More frequent safety evaluations may 
be performed if clinically indicated. The final scheduled safety assessment will occur at t he End 
of Treatment Visit. If the study  treatment is held due to AEs, I nvestigators should perform 
additional safety assessments as clinically indicated.  
Radiographic evaluation of tumor burden (e.g., diagnostic computed tomography [ CT] scan with 
intravenou s contrast or MRI) will occur during Screening  (within 28 days prior to 
randomization) , every 8 weeks after C1D1 for the first 12 cycles, every 12  weeks beginning with 
Cycle 13, and at the End of Treatment Visit . Radiographic a ssessments may occur  more 
frequently as clinically indicated.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 32  Quality of life questionnaires will be completed  before study drug dosing on C1D1, every 
4 weeks after C1D1 for the first 1 2 cycles, every 12 weeks beginning with Cycle  13, and at the 
End of Treatment Visit.  
Patients who hold or discontinue only one of the study drugs (either CB-839/placebo or 
cabozantinib) for any reason such as , but not limited to, an AE or surgery, should continue the 
other study drug on study and continue to have scheduled study visits and proc edures per 
protocol.  
10.4 Long Term Follow Up  
Patients who are in long -term survival follow -up should be contacted every 3 mo for the first 
12 mo following discontinuation of all study treatment s (CB-839/placebo and cabozantinib)  and 
every 6 mo thereafter.  All reasonable efforts must be made to contact the patient and/or persons 
authorized by the patient  to collect survival  status and subsequent anticancer therapy .  
10.5 Screen Failures  
Patients who sign an informed consent form  but are not randomized into the st udy are defined as 
screen failures.  For all screen failures, the following information will be captured in the 
electronic data capture (EDC) system: screening number, patient demographics , reason(s) for 
screen failure , and serious adverse events ( SAEs) for study-related procedures through 30  days 
after the procedure , if applicable .  
10.6 Procedure details  
This section describes assessments to be performed and recorded in the EDC  system.  
Routine safety and tolerability will be evaluated from the results of reported signs and 
symptoms, scheduled physical examinations, vital sign measurements, 12 -lead ECGs, and 
clinical laboratory test results.  
Please refer to Attachment 1  for the schedule of study assessment s. Unscheduled visit s and 
additional assessments may be performed as clinically indicated at any time.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 33  10.6.1 Demographics, Medical, and Cancer History  
Demographics at screening will include date of birt h (or age if date of birth is not allowed to be 
collected by local regulations ), patient initials, race and ethnicity.  Additional information such as 
medical and cancer history, surgical history, prior radiation hist ory, and prior systemic anticancer 
treatment history  will also be collected.  
10.6.2 Physical Examination  
Complete physical examinations will be performed by a licensed physician (or physician‚Äôs 
assistant or nurse practitioner) at Screening and the End of Treatment  Visit. Symptom -directed 
physical exam s can be done on all other visits. System exams are only required as clinically 
indicated.  
The KPS score  (Attachment 4 ) will be assessed during S creening to determine the patient‚Äôs 
eligibility and prognostic risk score accordin g to IMDC criteria (Attachment  3). The KPS will 
also be used to evaluate the patient‚Äôs performance at scheduled clinic visits according to 
Attachment  1.  
10.6.3 Vital Signs  
Vital signs (blood pressure, respiratory rate, pulse rate, and temperature) wi ll be obtained in the 
sitting position.  All patients should be sitting for at least 3 min prior to obtaining vital signs.  
10.6.4 Adverse Events  
Adverse event information will be collected at study visits and may also be collected via any 
other forms of communic ation any time during the study . See Section 15.0 for additional details 
on recording and reporting AEs and SAEs .  
10.6.5 Concomitant Medications  
Concomitant medication information will be collected at study visits and may also be collected 
via any other forms of communication  any time during the study . See Section 10.1.1 for details 
on permitted and protocol -restricted concomitant treatment.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 34  10.6.6 Electrocardiograms  
Patients should rest in the supine or semi-recumbent position for at least 5 min before the 12-lead 
ECG recording is started.  ECG reco rdings must be performed using a standard, high -quality, 
high-fidelity electrocardiograph machine equipped with computer -based interval measurements.  
When performed, the ECG must be reviewed by a qualified physician (or qualified physician‚Äôs 
assistant or nurse practitioner), and any clinically important finding should be recorded on the 
appropriate electronic case report form ( eCRF). ECG resu lts will include heart rate, R -R interval , 
PR interval, QRS interval, QT interval, and QTc interval.   
10.6.7 Laboratory Ass essments  
Laboratory evaluations will be performed as noted in the Schedule of Study Assessment s 
(Attachment 1 ). The laboratory analytes are listed in Attachment 2 . All laboratory assessments 
will be completed by the site local laboratory and results entered in the EDC  system.  
Any clinically significant results should be entered as medical history or adverse events in the 
EDC system.  
10.6.8 Patient-Reported Quality of Life Assessment  
Quality of life  assessments should be completed as scheduled relative to the date of C1D1  
regardless of study treatment holds or delay  (see Attachment  1). 
Patients will be asked to complete two health related QoL assessments.  The first is the NCCN -
Functional Assessment of Cancer Therapy  - Kidney Symptom Index ( FKSI-19) questionnaire , 
and the second is the EuroQol Health questionnaire ( EQ-5D-5L).  
Patients should complete the qu estionnaires prior to receiving any information on their most 
recent medical results in order to ensure that their responses will  not be influenced by their 
medical information when completing the questionnaires . If a clinic visit is not possible, patients  
should complete the questionnaires as per schedule at home and transmit their responses to the 
site (e.g., mail or email) or return it to the site during the next visit.  Upon completion, the site 
should carefully review for completeness.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 35  10.6.9 Tumor Assessment s 
Radiographic tumor assessments should be completed as scheduled relative to the date of 
C1D1 regardless of study treatment holds or delay (see Attachment  1). 
Radiographic tumor assessme nts will include diagnostic quality imaging ( CT scan or MRI) of 
chest/abdomen/pelvis . For patients who have  an MRI of the abdomen and pelvis , a CT scan of 
the chest is also required . An MRI or CT of the brain will also be performed at screening for 
patients with known or suspected brain meta stases and continued post -baseline as clinically 
indicated. If a CT of the brain is performed, ambiguous results must b e confirmed by MRI. For 
patients with symptoms of spinal compression, MRI of the spine and base of the skull should 
also be performed. Whole body bone scans will also be performed at screening for patients with 
known or suspected bone metastases and continued post -baseline as clinically indicated . 
The study -specific Imaging Manual should be followed.  To ensure image consistency, the same 
imaging modality and acquisition protocols at the same institution/facility used at screening 
should be used for subsequent tumor assessments.  Ideally contrast -enhanced imaging should be 
performed at screening and subsequent assessments, including at least p ost-contrast CT scan of 
the chest and post -contrast CT or MRI  of the abdomen and pelvis. If CT contrast is 
contraindicated, a non -contrast CT scan of the chest together with contrast -enhanced  MRI of the 
abdomen and pelvis is strongly recommended. If CT or MRI contrast is contraindicated in 
follow-up tumor assessments  after contrast -enhanced imaging at baseline , the same modality 
without contrast should be performed. All imaging must be acquired and transmitted for central 
review in original Digital Im aging and Communications in Medicine ( DICOM) format per 
guidelines in the study -specific imaging manual .  
For the purpose of patient management and treatment decisions  during the course of the study , 
radiographic response and disease progression will be as sessed locally by investigators using 
RECIST v1.1 ( Attachment 5 ). For the purpose of robust documentation of radiographic 
progression per IRC : 
ÔÇ∑ If any doubt or ambiguities exist  about radiographic progression , Investigators are 
encouraged to continue study therapy if the patient is tolerating treatme nt, repeat 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 36  radiographic studies at the next scheduled time, and delay determination of progression 
until the findings indicating radiographic progression are unequ ivocal.  
ÔÇ∑ Patients who discontinue study treatment for reasons other than progressive disease by 
RECIST v1.1 or death will continue to be followed by radiographic tumor imaging until 
documentation of radiographic progressive disease per RECIST  v.1.1, death,  initiation of 
a new anticancer therapy, or withdrawal of consent .  
ÔÇ∑ If study treatment continues beyond Investigator -assessed progression because the patient 
is receiving clinical benefit from continued treatment (see Section 11.3), radiographic 
tumor assessments will also continue until the patient discontinues study treatment . This 
practice has the benefit of providing radiographic studies for IRC review beyond 
Investigator -assessed progression, which may be helpful in the case of  discordance 
between the Investigator and the IRC regarding the date of progression.   
10.6.10 Tumor Biopsies  
10.6.10.1 Archival Tumor Biopsies  
Archival tumor samples will be provided from all patients unless the archival sample is 
unavailable. Archival samples should be collected and shipped according to instructions 
provided in the laboratory manual. Archival tissue blocks or slides freshly cut from those blocks 
are strongly preferred, due to the concern of tissue stability after exposure.  Archival tissue 
collected from recent time points before enrollment is preferred because it more accurately 
reflects the current state of the tumor/microenviro nment at the time of study entry.   
10.6.10.2 Optional Fresh Tumor Biopsies  
At North American sites only, o ptional tumor biopsies , collected as clinically indicated at any 
point on the study , may be shared with the Sponsor upon patient consent for exploratory 
biomarker assessment  (e.g., predictive/prognostic biomarkers for response) . Unless clinically 
indicated, b iopsies should not be obtained from target lesions being followed for disease 
assessment  prior to documentation of disease progression per RECIST  v.1.1.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 37  When obtained, t issue from optional tumor biopsies will be used for 1) the analysis of gene 
expression levels, 2) immunohistochemical/immunofluorescence analysis, and 3) mutation 
profiling. Tissue may also be used for the evaluation of additional explorato ry biomarkers that 
are not pre -specified in this protocol based upon new scientific literature and/or preclinical data.  
10.6.11 Pharmacokinetic Sample s 
Pharmacokinetic  samples will be collected from  all patients . Plasma PK samples will be used to 
measure concentra tions of CB-839, 110826 (the major metabolite of CB -839), and cabozantinib , 
and may be used to measure other associated analytes by using a validated liquid 
chromatography tandem mass spectrometry (LC -MS/MS) method of appropriate specificity and 
sensitivity according to GLP . Blood samples for PK analysis will be collected at the following 
time points: 
ÔÇ∑ Cycle 2 Day 1: Pre-dose and 2 hr post dose (¬± 30 min ). Patients must take their morning 
dose of CB-839 in the clinic.  
ÔÇ∑ Cycle 3, Day 1: 4 hr and 6 hr post dose (¬± 1 hr). Patients can take their morning dose of 
CB-839 in the clinic or at home.  
The actual time of collection must be noted in the source documents and eCRFs.  On Cycle  2 
Day 1, patients will have to arrive at the clinic to get their pre -dose PK sample  drawn prior to 
taking their dose  in the clinic . Patients must record the time s they take their evening dose before 
Cycle 2 Day 1 and their morning dose on Cycle 3 Day 1 (if they take it at home) . In the event 
that CB-839/placebo dosing is interrupted with in 3 days before visits with  PK sampling, PK 
samples should be collected during the next visit that the patient is in the clinic  and has taken at 
least 3 consecutive days of CB -839/placebo . Please consult with the Medical Monitor to 
determine best options for making up missed PK samples.  
Refer to the laboratory manual for details on collection kits and sample processing.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 38  10.6.12 Pregnancy, Contraception and Nursing/Breast-feeding 
Patients should be informed that taking the study drugs may involve unknown risks to a  fetus 
(unborn baby) if pregnancy were to occur during study treatment exposure . In order to 
participate in the study, patients must adhere to pregnancy testing and contraception 
requirements described below  (Clinical Trial Facilitation Group  2014).  
10.6.12.1 Pregnancy Testing  
All women who are being considered for participation in the study, and who are not surgically 
sterilized or postmenopausal  (defined as without menses for >1  year without an alternative 
medical cause), will have a serum or urine  pregnancy test during screening , on C1D1 predose (if 
screening test > 3 days before  receiving the first dose of study treatment ), and at the End of 
Treatment Visit . If a urine test is positive or borderline (unable to confirm as negative), a serum 
Œ≤-hCG test will be required. Patients must be excluded in the event of a posi tive or borderline 
test result that is not confirmed as negative. Patients who bec ome pregnant on study will be 
required to discontinue study treatment. Pregnancies occurring during and up to 6 months after 
completion of study treatment will be reported and followed for outcomes (see Section 15.1). 
10.6.12.2 Contraception  
Sexually active patients with heterosexual partners must agree that they and their partners will 
use dual methods of  contraception to prevent pregnancy during the course of study treatment and 
through 4 months after  the last dose of  all study treatment.  Surgically sterilized or 
postmenopausal female patients (no menses for > 1 year  without an alternative medical cause ) or 
male patients with surgically ste rilized or postmenopausal female partners  are exempt from these 
requirements.  Patients who choose abstinence are exempt from a second method of 
contraception.  Male patients must include a barrier method of contraception (preferably male 
condom) if sexually  active with a female partner of childbearing potential.  
Contraception must include a t least one  highly effective method . Highly effective methods of 
contraception include:  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 39  ÔÇ∑ combined (estrogen and progestogen containing) hormonal oral, intravaginal or 
transdermal contraception associated wit h inhibition of ovulation  
ÔÇ∑ progestogen -only hormonal oral, injectable, or implantable contraception associated with 
inhibition of ovulation  
ÔÇ∑ intrauterine device  
ÔÇ∑ intrauterine hormone -releasing system  
ÔÇ∑ vasectomised partner  
ÔÇ∑ sexual abstinence  
Additional acceptable m ethods of contraception that are  not considered highly effective include:  
ÔÇ∑ progestogen -only oral hormonal contraception, where inhibition of ovulation is not the 
primary mode of action  
ÔÇ∑ male or female condom with or without spermicide  
ÔÇ∑ cap, diaphragm or sponge with spermicide  
The following birth control methods are considered unacceptable:  
ÔÇ∑ periodic abstinence (calendar, symptothermal, post -ovulation methods)  
ÔÇ∑ withdrawal (coitus interruptus)  
ÔÇ∑ spermicides only  
ÔÇ∑ lactational  amenorrhoea method  
Because the absence of pharmacokinetic interactions between hormonal contraception and study 
treatment cannot be  guaranteed , patients should also be counselled that there is potential for 
hormonal contraception to be less effective. Therefore, if a hormonal contraception is chosen as 
the highly effective hormonal method, the second method of contraception should be a barrier 
method (preferably male condom).  
Male patients must also agree to  refrain from donating sperm during the study and for a 
minimum of 4  mo following the last dose of all study treatment . 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 40  If there is any question that a patient will not reliably c omply with the requirements for 
contraception, that patient should not be entered into the study.  
10.6.12.3 Nursing/Breast-feeding 
It is not known whether the study drugs and/or their  metabolites are excreted in human milk. 
Because of the potential harm to the infan t, mothers should discontinue nursing/breast-feeding 
during treatment with study all study drugs  and for at least 4 months after completing therapy.  
11.0 POTENTIAL TOXICITIES , DOSE MODIFICATION AND MANAGEMENT OF 
TOXICITIES  
11.1 Potential Toxicities  
11.1.1 CB-839 
The most f requent AEs considered possibly or probably related to CB -839 monotherapy dosed 
on the BID schedule on the Phase 1 CX-839-001 study were fatigue, gastrointestinal events 
(nausea, vomiting, and constipation), photophobia, anemia, dyspnea, and elevations in liver 
function tests  (see Table 9.5-1). These have been primarily Grade 1/2 AEs that have been 
manageable and reversible with minimal dose modifications or delays.  
The most frequent Grade 3/4 AEs considered possibly  or probably re lated to monotherapy 
CB-839 were LFT elevations (see Table 9.5-1).  
11.1.2 Cabozantinib  
The safety and tolerability profile of cabozantinib is well defined and outlined in the Cabometyx 
(cabozantinib ) US Prescribing Information (or local equivalent) . A summary is provided below:  
Adverse events most frequently observed with cabozantinib (‚â•25% of patients) are diarrhea, 
fatigue, nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome , hypertension, 
vomiting, weight decreased, and constipation . The majority of these AEs have been of mild to 
moderate severity (CTC AE Grade 1-2). Grade 3-4 adverse reactions and laboratory 
abnormalities which occur red in ‚â• 5% of patients were hypertension, diarrhea, fatigue, palmar -
plantar erythrodysesthesia syndrome, hyponatremia, hypophosphatemia, hypomagnesemia, 
lymphocytes decreased, anemia, hypokalemia, and GGT increased.  Cabozantinib has been 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 41  associated with a  low incidence of severe  and potentially lethal AEs, including  hemorrhage, GI 
perforations and fistulas, thrombotic events, hypertension and hypertensive crisis, diarrhea, 
palmar-plantar er ythrodysesthesia syndrome , reversible posterior leu koencephalopathy  
syndrome , and embryo -fetal toxicity (see Warnings and Precautions in the Cabometyx 
(cabozantinib) US Prescribing Information [or local equivalent] ).  
11.1.3 Dose Modification Guidelines  
11.1.3.1 Study Drug Dose Levels  
The possible dose levels for CB -839/placebo and caboz antinib are provided in  Table 11.1-1 and 
Table 11.1-2.  
Table 11.1-1: Dose Levels for CB -839/Placebo  
Dose Level  CB-839/Placebo Dose  
Starting dose  800 mg BID  (1600 mg daily)  
First dose reduction  600 mg BID  (1200 mg daily)  
Second dose reduction  400 mg BID  (800 mg daily)  
Third dose reduction  Discontinue  
 
Table 11.1-2: Dose Levels for Cabozantinib  
Dose Level  Cabozantinib Dose  
Starting dose  60 mg oral QD  
First dose reduction  40 mg oral QD  
Second dose reduction  20 mg oral QD  
Third dose reduction  Discontinue  
 
11.1.3.2 Study Drug Dose M odifications  
Dose modifications may be considered for each study drug independently. Modifications, 
including dose interruption  and resumption , dose reduction, dose re -escalation, and permanent 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 42  discontinuation of each study drug will be based on the invest igator‚Äôs discretion, with the 
following exceptions:  
ÔÇ∑ The dose of each study drug  cannot exceed  the starting dose  
ÔÇ∑ Interruptions of study drug are allowed for up to 6 weeks (continuous) without Medical 
Monitor consultation, althou gh it is strongly recommended  that interruptions in dosing 
are as brief as possible. Resumption of study drug  in a patient  with a dose  interruption 
lasting > 6 weeks requires discussion with and approval  by the Medical Monitor (see 
Section 11.2) 
ÔÇ∑ Both study drugs should be interrupted for Grade ‚â• 3 elevated ALT, AST, or bilirubin 
and restarted at reduced dose s after ALT, AST, and bilir ubin levels resolve to Grade ‚â§ 1 
or baseline  
ÔÇ∑ Suspected drug-induced liver injury should be reported to the Medical Monitor; both 
study drugs should be interrupted and then resumed only after discussion with and  
approval by the Medical Monitor (see Section 11.1.4.2) 
ÔÇ∑ Dose re-escalation is not allowed for a dose reduction triggered by study drug -related 
myelosup pression or Grade  4 life-threatening AEs affecting major organs  
ÔÇ∑ Permanently discontinue cabozantinib for any of t he following:  
o Development of unmanageable fistula or GI perforation  
o Severe hemorrhage  
o Arterial thromboembolic event (e.g., myocardial infarction, cerebral infarction)  
o Hypertensive crisis or severe hypertension despite optimal medical management  
o Nephrotic s yndrome 
o Reversible posterior leukoencephalopathy syndrome  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 43  Additional guidelines for treatment modifications and AE management are provided below in 
Table 11.1-3 and in Section 11.1.4. These guidelines  are based on the Cabometyx (cabozantinib) 
US Prescribing Information and the clinical experience with CB -839, cabozantinib, and the 
combination to date. Because cabozantinib  prescribing information may change over time, the 
most up-to-date Cabometyx (cabozantinib) US Prescribing Information (or local equivalent) 
should also be consulted and followed.  
These guidelines are intended primarily for toxicities that investigators a ssess as related to study 
treatment  (CB-839/placebo or cabozantinib) and that are not easily managed with routine 
supportive care. In general, all AEs should be managed with supportive care at the earliest signs. 
Dose interruptions of cabozantinib should b e as brief as possible.   
Unless otherwise specified (see exceptions under Study Drug Dose Modifications above ), dose 
modifications and AE management guidelines  presented in this protocol are only 
recommendations  and are not intended to supersede the clinic al judgment of the treating 
physician.   
Table 11.1-3: Treatment Modifications Guidelines for Treatment -Related AEs  
Toxicity Grade 
(CTCAE v4)  CB-839/Placebo  Cabozantinib  
Grade 1-2 If manageable and tolerable, continue current dose with supportive care.  
If not tolerable, interrupt dosing and resume at same dose level upon recovery. 
If Grade 2 toxicity recurs, interrupt and restart at next lower dose.  
Grade 3  
(except non -
clinically 
relevant 
laboratory 
abnormalities)  Interrupt dosing and resume at the 
same dose level or next lower 
dose level upon recovery.  Interrupt dosing, unless toxicity can be 
easily managed with a dose reduction, and 
resume at the next lower dose level upon 
recovery.  
Grade 4  
(except non -
clinically 
relevant 
laboratory 
abnormalities)  Interrupt dosing immediately. Discontinue study drug unless the patient is 
deriving clear clinical benefit, as determined by the investigator and agreed by 
the Medical Monitor, and the toxicity can be managed with a dose redu ction 
and optimal medical care . 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 44  11.1.4 Cabozantinib Warnings, Precautions, and Guidelines for Management of 
Potential Adverse Events  
Below are guidelines for the treatment and/or prevention of ce rtain treatment -emergent AEs of 
interest that have been associated with, or have a theoretical  possibility of occurring with, 
cabozantinib treatment.  
11.1.4.1 Gastrointestinal Disorders  
The most common GI AEs reported in clinical studies with cabozantinib are diarrhea, oral pain, 
dyspepsia, stomatitis, and dysphagia.  
Diarrhea  
Patients should be instructed to notify their study doctor or site staff immediately at the first 
signs of poorly formed or loose stool or an increased frequency of bowel movements. 
Administration of antidiarrheal/ antimotility agents is recommended at the  first sign of diarrhea 
as initial management. Some patients may require concomitant treatment with more than one 
antidiarrheal agent. When therapy with antidiarrheal agents does not control the diarrhea to 
tolerable levels, consider temporary  dose interruption or reduction per Table 11.1-3. When the 
diarrhea is controlled, retreatment with study treatment may be acceptable per investigator 
decision. 
In addition, general supportive measures should be implem ented including continuous oral 
hydration, correction of fluid and electrolyte abnormalities, sma ll frequent meals, and stopping 
lactose-containing products, high fat meals, and alcohol.  
Nausea and Vomit ing 
Antiemetic agents are recommended as clinically appropriate at the first sign of nausea and 
vomiting or as prophylaxis to prevent emesis, along with supportive care according to clinical 
practice guidelines. The 5 -HT3 receptor antagonists are recommend ed over chronic use of NK -1 
receptor antagonists and dexamethasone (NK -1 receptor antagonists can induce or inhibit 
CYP3A4, and glucocorticoids induce CYP3A4 and thus could lower cabozantinib exposure ). 
Caution is also recommended with the use of nabilone,  which is a weak inhibitor of CYP3A4.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 45  Stomatitis and Mucositis  
Preventive measures may include a comprehensive dental examination to identify any potential 
complications before study treatment is initiated. Removal of local factors should be instituted as  
indicated, such as modification of ill -fitting dentures and appropriate care of gingivitis. During 
treatment with cabozantinib good oral hygiene and standard local treatments such as 
nontraumatic cleansing and oral rinses ( e.g., with a weak solution of sa lt and baking soda) should 
be maintained. The oral cavity should be rinsed and wiped after meals, and dentures should be 
cleaned and brushed often to remove plaque. Local treatment should be instituted at the earliest 
onset of symptoms. Obtain bacterial/vi ral culture if oral infection is suspected and treat infection 
as indicated by local guidelines. When stomatitis interferes with adequate nutrition and local 
therapy is not adequately effective, dose reduction or temporary withholding of cabozantinib 
should be considered.  
11.1.4.2 Hepatobiliary Disorders  
Elevations of ALT, AST, and bilirubin have been observed during treatment with cabozantinib. 
It is recommended that patients with elevation of ALT, AST, and/or bilirubin have more frequent 
laboratory monitoring of t hese parameters. If possible, hepatotoxic concomitant medications 
should be discontinued in patients who develop increased values of ALT, AST, or bilirubin.  
Patients on this study may enter with increased ALT/AST serum levels up to 3 √ó ULN. Dose 
reductions  of study treatment should be considered in any patient who develops drug -related 
Grade 2 elevated ALT, AST, or bilirubin lasting longer than 1 week. A patient who develops 
Grade ‚â• 3 elevated ALT, AST, or bilirubin should have study treatment held and restarted at a 
reduced dose (see Table 11.1-3) after ALT, AS T, and bilirubin levels resolve to at least 
Grade ‚â§ 1 or baseline. In patients with recurrence of drug -related Grade ‚â• 3 elevated ALT, AST, 
or bilirubin at the lowest dose level, study treatment should be discontinued. In patients who 
develop ALT/AST eleva tions > 3 √ó ULN in combination with a bilirubin elevation > 2 √ó ULN 
without reasonable other explanation, drug -induced liver injury should be suspected and study 
treatment interrupted. Reinstitution of study treatment after recovery of ALT, AST, and biliru bin 
to Grade 1 or baseline level must be discussed and approved with the Sponsor.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 46  11.1.4.3 Hematological Disorders  
Hematological toxicities ( i.e., neutropenia and thrombocytopenia) and associated complications  
have been observed after administration of cabozantinib  and may be managed  with dose 
interruptions and/or dose reductions. Use of granulocyte colony -stimulating factor support for 
neutrophil recovery is allowed per investigator discretion and in accordance with accepted 
guidelines after the first incidence of clinically relevant  cytopenia.  
Complete blood counts with differentials and platelets should b e performed regularly. Patients 
with hematologic toxicities may require additional or more frequen t laboratory tests according to 
institutional guidelines.  
Febrile neutropenia or evidence of infection associated with neutropenia must be assessed  
immediately and treated appropriately and in a timely ma nner according to institutional 
guidelines.  Dose reductions or dose interruptions for anemia are not  mandated but can be applied 
as clinically indicated. Supportive care such as red blood c ell transfusions may be managed 
according to institutional guidelines.  
11.1.4.4 Fatigue, Anorexia, and Weight Loss  
Fatigue has been reported during treatment with cabozantinib. Common ca uses of fatigue such as  
anemia, deconditioning, emotional distress (depression an d/or anxiety), nutrition, sleep 
disturbance, and hypothyroidism should be ruled out and/or these causes t reated according to 
standard of care. Individual non -pharmacological a nd/or pharmaco logic interventions directed to 
the contributing and treatable factors should be given. Pharmacological management with 
psychostimulants such as methylphenidate should be co nsidered after disease specific 
morbidities have been excluded. Note:  Chronic use of modafinil s hould be avoided because of its 
potential to reduce cabozantinib exposure . 
Dose reduction of study treatment should be considered when general or pharmacological 
measures have not been successful in reducing symptoms. Dose interr uption may be considered  
for Grade ‚â• 3 fatigue despite optimal management, at the investigator‚Äô s discretion.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 47  Anorexia and weight loss should be managed according to l ocal standard of care including 
nutritional support. Pharmacologic therapy such as megest rol acetate should be considered for 
appetite enhancement. Should these interventions prove ineffective, dose hold and reductions  
may be considered for Grade ‚â• 3 anorexia or weight loss. If ano rexia and/or weight loss do not 
recur after a dose reduction, d ose of cabozantinib may be re -escalated to the previous dose.  
11.1.4.5 Skin Disorders  
Palmar-plantar erythrodysesthesia syndrome   
Palmar-plantar erythrodysesthesia (PPE) syndrome (also known as  hand-foot syndrome), skin 
rash (including blisters, erythematous rash, macular rash, skin exfolia tion, dermatitis acneiform, 
and papular rash), pruritus, dry skin, and erythema have been r eported in cabozantinib -treated 
patients. All patients on study should be advised on prophylactic s kin care. This includes the use 
of hypoallergenic moisturizing creams, ointment for dry skin, an d sunscreen with sun protection 
factor ‚â• 30, avoidance of exposure of hands and feet to hot water, protection of pressure -
sensitive areas of hands and feet, and use of thick cotton gloves and socks to prevent injury and 
to keep the palms and soles dry. Patients with skin disorders sh ould be carefully monitored for 
signs of infection ( e.g., abscess, cellulitis, or impetigo).  
Early signs of hand -foot syndrome could be tingling, numbn ess, and slight redness or mild 
hyperkeratosis. Early manifestations include painful, symmetric al red and swollen areas on the 
palms and soles. The lateral sides of the fingers or peri -ungual zones may also be affected. 
Adequate interventions are required to preven t worsening of skin symptoms such as blisters, 
desquamations, ulcerations, or necrosis of affected areas. Aggressive management of symptoms  
is recommended, including early dermatology referral. Treatmen t guidelines for PPE related to 
study treatment are pr esented in  Table 11.1-4. 
In the case of study treatment -related skin changes ( e.g., rash, hand -foot syndrome), the 
investigator may request that additio nal assessments be conducted with the patient‚Äôs consent. 
These assessments may include digital photographs of the skin  changes and/or a biopsy of the 
affected skin and may be repeated until the skin changes resolve.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 48  Table 11.1-4: Management of Treatment -emergent PPE Syndrome  
CTCAE v.4.0 
Grade  Action To Be Taken  
1 Cabozantinib treatment may be continued at the current dose if PPE is clinically 
insignificant and tolerable. Otherwise, cabozantinib sho uld be reduced to the next 
lower dose level. Start urea 20% cream twice daily and clobetasol 0.05% cream once 
daily. Reassess at least weekly; if PPE worsens at any time or does not improve after 
2 weeks, proceed to the intervention guidelines for Grade 2.  
2 Cabozantinib treatment may be continued if PPE is tolerated. Cabozantinib should be 
dose reduced or interrupted if PPE is intolerable. Continue urea 20% cream twice 
daily and clobetasol 0.05% cream once daily and add analgesics ( e.g., 
NSAIDs/GABA agonists) for pain control if needed. Reassess at least weekly; if 
PPE does not improve within 2 weeks or worsens or affects self -care, proceed to the 
intervention guidelines for Grade 3.  
3 Interrupt cabozantinib treatment until severity decreases to Grad e 1 or 0.  
Continue treatment of skin reaction with clobetasol 0.05% cream twice daily and 
analgesics. Resume cabozantinib at reduced dose if PPE recovers to Grade 1 or 0 . 
Discontinue patient from study if intolerable PPE recurs after dose reduction or doe s 
not improve within 6 weeks.  
CTCAE, Common Terminology Criteria for Adverse Events; GABA, gamma -amino butyric acid;  
NSAID, non -steroidal anti -inflammatory drug; PPE, palmar -plantar erythrodysethesia.  
 
Wound Healing and Surgery  
VEGF inhibitors can cause wound healing complications  and wound dehiscence which may 
occur even long after a wound has been considered healed. Th erefore, surgical and traumatic 
wounds must have completely healed prior to starting cabozant inib treatment and be monitored 
for wound de hiscence or wound infection while the patient is being treated with cabozantinib.  
11.1.4.6 Hypertension  
Hypertension is a common class effect of drugs that inhibit VEGF pathways and has been  
reported in patients treated with cabozantinib.  
Blood pressure should be monitored in a constant position at each vi sit (either sitting or supine). 
Treatment guidelines for hypertension deemed related to cabozanti nib are presented in Table 
11.1-5. In general, patients with known hypertension should be optimall y managed prior to study 
entry. Decisions to decrease or hold the dose of study treatment must b e based on blood pressure 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 49  readings taken by a medical professional and mus t be confirm ed with a second measurement at 
least 5 minutes following the first measurement. Other than for hypertension requiring  
immediate therapy, the presence of new or worsened hypertension should be confirmed at a  
second visit before taking therapeut ic action. It is recommende d that this second visit occurs 
within 1 week.  
Table 11.1-5: Management of Treatment -emergent Hypertension  
Criteria for Dose  
Modification  Action To Be Taken  
> 150 to <160 mm Hg (systolic)  
OR 
> 100 to <110 mm Hg (diastolic)  ÔÇ∑ Optimize antihypertensive treatment by adding new or  
additional antihypertensive medications and/or  increase 
dose of existing medications.  
ÔÇ∑ Reduce cabozantinib treatment by one dose level if  
optimal anti hypertensive therapy (usually to include  3 
agents) does not result in BP < 150 mm Hg systolic  or < 
100 mm Hg diastolic.  
ÔÇ∑ If patient is symptomatic interrupt study treatment.  
‚â• 160 mm Hg (systolic)  
OR 
‚â• 110 mm Hg (diastolic)  ÔÇ∑ Reduce cabozantinib treatment by  one dose level and  add 
new or additional antihypertensive medications  and/or 
increase dose of existing medications and  monitor patient 
closely for hypotension. If optimized  antihypertensive 
therapy (usually to include 3 agents)  does not result in BP 
< 150 mm Hg systolic or  < 100 mm Hg diastolic, 
cabozantinib treatment should  be dose reduced further or 
interrupted.  
ÔÇ∑ Interrupt cabozantinib treatment if upper limits of BP  
(‚â• 160 mm Hg systolic or ‚â• 110 mm Hg diastolic) are  
sustained and not adequately manageab le or if BP is  
> 180 mm Hg systolic or > 120 mm Hg diastolic or if  
patient is symptomatic.  
ÔÇ∑ Restart cabozantinib treatment at the most tolerable  dose 
and re-escalate cabozantinib dose only if BP falls  to and is 
sustained at < 140 mm Hg systolic and  < 90 mm Hg 
diastolic. 
Hypertensive crisis or  
hypertensive encephalopathy  ÔÇ∑ Discontinue cabozantinib treatment  
BP, blood pressure.  
 
11.1.4.7 Thromboembolic Events  
Thromboembolic complications are frequent in cancer patients due to procoagulant changes  
induced by the malignancy or anti -cancer therapy including in hibitors of VEGF pathways. Deep 
vein thrombosis and PE have been observed in clinical studies with cabozantinib; including fatal 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 50  events. Patients who develop a PE or DVT should have cabozantinib treatment held until 
therapeutic anticoagulat ion with heparins ( e.g., LMWH) is established. (Note: Initiation of 
therapeutic anticoagulation is allowed on study in consultation with the Sponsor‚Äôs medical 
monitor.) Cabozanti nib treatment may be resumed in patients who are  stable and have 
uncomplicated PE or DVT an d are deriving clinical benefit from cabozantinib treatment. During 
anticoagulation treatment, patients need to be monitored on an ongoing basis for bleeding risk 
and signs of bleeding which may require additional  or more frequent laboratory tests according 
to institutional guidelines. If th ere are any signs of clinically relevant bleedings, cabozantinib 
treatment should be interrup ted immediately and the sponsor contacted to discuss further study 
participation. Patients with life -threatening PE or DVT should have study treatment discontinued 
unless toxicity can be manage d and patient is deriving clear clinical benefit as determined by the 
investigator and agreed by the Sponsor.  
Arterial thrombotic events ( e.g., transient ischemic attack, m yocardial infarction) have been 
observed rarely in studies with cabozantinib. Patients should be  evaluated for preexisting risk 
factors for arterial thrombotic events such as diabetes mellitus , hyperlipidemia, hypertension, 
coronary artery disease, history of tobacco use, and cardia c or thromboembolic events that 
occurred prior to initiation of study treatment. Cabozantinib trea tment should be discontinued in 
patients who develop an acute myocardial infarction or any other clinicall y relevant arteria l 
thromboembolic complication.  
11.1.4.8 Proteinuria  
Proteinuria is an anticipated AE with the inhibition of VEGF pathways and has been observed in  
cabozantinib clinical studies, and nephrotic syndrome has been  reported with cabozantinib and 
other inhibitors of VEGF pathways.  Urine protein should be monitored regularly during 
cabozantinib treatment. Guidelines for p roteinuria management are d escribed in  Table 11.1-6. 
Cabozantinib should be discontinued in patients who develop nephrotic syndrome . 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 51  Table 11.1-6: Management of Treatment -emergent Proteinuria  
Severity of Proteinuria (UPCR)  Action To Be Taken  
‚â§ 1 mg/mg (‚â§ 113.1 mg/mmol)  No change in cabozantinib treatment or monitoring  
> 1 to < 3.5 mg/mg  
(> 113.1 to < 395.9 mg/mmol)  ÔÇ∑ No change in cabozantinib treatment required  
ÔÇ∑ Consider confirming with a 24 -hour protein assessment 
within 7 days  
ÔÇ∑ Repeat UPCR within 7 days and once per week. If UPCR < 1 
on 2 consecutive readings, UPCR monitoring can revert to 
protocol-specific times. (Second reading is confirmatory and 
can be done within 1 week of first reading.)  
‚â• 3.5 mg/mg (‚â• 395.9 mg/mmol)  ÔÇ∑ Hold cabozantinib treatme nt pending repeat UPCR within 
7 days and/or 24 -hour urine protein.  
ÔÇ∑ If ‚â• 3.5 on repeat UPCR, continue to hold cabozantinib 
treatment and check UPCR every 7 days. If UPCR decreases 
to < 2, restart cabozantinib treatment at a reduced dose and 
monitoring of urine protein/creatinine should continue 
weekly until the UPCR decreases to < 1.  
Nephrotic syndrome  Discontinue cabozantinib treatment  
UPCR, urine protein to creatinine ratio.  
 
11.1.4.9 Hypophosphatemia  
Hypophosphatemia has been reported during treatment with cabozantinib. Serum phosphorus  
should be monitored frequently while receiving cabozantinib. M ild hypophosphatemia is usually 
asymptomatic or symptoms can be non -specific such as weakness , bone pain, rhabdomyolysis, or 
altered mental status. Other causes of hypophosphatemia such as poor nutrition, chronic 
alcoholism, malabsorption, excessive antacid use, glucocort icoids use, kidney dysfunction, 
respiratory alkalosis, vitamin D deficiency should be rule d out and/or these causes treated 
according to standard of care. Mild to moderate hypophospha temia should be managed by oral 
replacement including food that are high in phosphate (diary i tems, meats, beans) and/or oral 
phosphate supplements according to st andard clinical practice guidelines.  Clinically relevant 
hypophosphatemia should be managed acc ording to the dose modification guidelines as outlined 
in Table 11.1-3 or as clinically indicated.  
11.1.4.10 Thyroid Function Disorders  
Changes in thyroid function tests (TFTs) and hypothyroidism have been reported with  
cabozantinib and other tyrosine kinase inhibitor treatment as a re sult of altered thyroid hormone 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 52  regulation by mechanisms that seem to be specific for each agent (Torino 2009). Preliminary 
data from ongoing studies indicate that treatmen t-emergent elevation of t hyroid stimulating 
hormone (TSH) by cabozantinib may be dose -dependent in fashion. Currently available data are 
insufficient to determine the mechanism of T FT alterations and its clinical relevance. Monitor 
thyroid function as outlined in Attachment  1. Management of thyroid dysfunction ( e.g., 
symptomatic hypothyroidism) shoul d follow accepted clinical practice guidelines.  
11.1.4.11 Hemorrhagic Events  
Hemorrhagic events have been reported with approved drugs that inhibit VEGF pathways as well 
as with cabozantinib. In order to mitigate risk of severe  hemorrhage, patients should be evaluated 
for potential bleeding risk factors prior to initia ting cabozantinib treatment and monitored for 
bleeding events with serial complete blood counts  and physical examination while on study. Risk 
factors for hemorrhagic events may include (but may not be limited to) the following:  
ÔÇ∑ Tumor of the lung with cavitary lesions or tumor lesions w hich invades, encases, or abuts 
major blood vessels. The anatomic lo cation and characte ristics of tumor as well as the 
medical history must be carefully reviewed in the selection  of patients for treatment with 
cabozantinib.  
ÔÇ∑ Recent or concurrent radiation to the thoracic cavity  
ÔÇ∑ Active peptic ulcer disease, ulcerative coliti s, and other inflammatory GI diseases  
ÔÇ∑ Underlying medical conditions which affect normal hemostasi s (e.g., deficiencies in clotting 
factors and/or platelet function, or thrombocytopenia)  
ÔÇ∑ Concomitant medication with anticoagulants or other drugs which affect  normal hemostasis  
ÔÇ∑ History of clinically significant hemoptysis  
Discontinue cabozantinib treatment in patients who have been d iagnosed with a severe bleeding 
complication.  
11.1.4.12 GI Perforation/Fistula and Non -GI Fistula Formation  
GI perforation/fistula and non -GI fistula formation have been reported with approved drugs that 
inhibit VEGF pathways as well as with cabozantinib. Carefully monitor for episodes of 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 53  abdominal pain, especially in patients with known risk factors for developing GI 
perforation/fistula or no n-GI fistula, to allow for early diagnosis. Such risk factors include (but 
may not be limited to) the following:  
GI perforation/fistula:  
ÔÇ∑ Intra-abdominal tumor/metastases invading GI mucosa  
ÔÇ∑ Active peptic ulcer disease, inflammatory bowel disease, diverticul itis, cholecystitis or 
symptomatic cholangitis, or appendicitis  
ÔÇ∑ History of abdominal fistula, GI perforation, bowel obstruction, or intra -abdominal abscess  
ÔÇ∑ Prior GI surgery (particularly when associated with delayed or incomplete healing).  
Complete healing  following abdominal surgery or resolution of intra -abdominal abscess must 
be confirmed prior to initiating treatment with cabozantinib.  
Additional risk factors include concurrent chronic use of steroid treatment or nonsteroidal anti -
inflammatory drugs. Co nstipation indicative of bowel obstruction should be monitored and 
effectively managed.  
Non-GI fistula:  
Complications from radiation therapy has been identified as a possible predisposing risk factor 
for non-GI fistula formation in patients undergoing treatment with VEGF pathway inhibitors 
(e.g., bevacizumab).  Discontinue cabozantinib treatment in patients who have been diagnosed 
with GI or non -GI perforation/fistula.  
11.1.4.13 Osteonecrosis of the Jaw  
Osteonecrosis of the jaw (ONJ) has been reported  with use of anti -angiogenic drugs and 
bisphosphonates and denosumab in cancer patients. Additional risk factors for ONJ have been 
identified such as use of corticosteroids, chemotherapy, local radiotherapy, poor oral hygiene, 
smoking, dental or orofacial surgery procedures, and cancer disease itself. Osteonecrosis has 
been reported in patients treated with cabozantinib. As a preventive measure, invasive dental 
procedures should be avoided if possible in patients who have previously been treated with or 
concomitantly receive bisphosphonates or denosumab.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 54  In cases where dental procedures are unavoidable, the risks and benefits of a dental procedure 
and the extent of the procedure as well as the risk of developing osteonecrosis of the jaw need to 
be conside red when deciding on the duration of a temporary treatment interruption of 
cabozantinib. If clinically possible, treatment with cabozantinib should be held for approximately 
4 weeks prior to a dental procedure and resumed after complete healing has occurre d. 
Patients with any documented case of osteonecrosis should have study treatment interrupted, and 
appropriate clinical management should be initiated. Reinitiation of study treatment must be 
discussed with and approved by the Sponsor on a case -by-case basis. 
11.2 Resumption of Study Treatment  
After withholding a study drug for an adverse event  suspected to be related to that study drug , it 
is generally recommended that administration of the study drug  is resumed  when the AE has 
returned to ‚â§ Grade 1 or baseline ; however, investigator discretion may be used to determine if 
resolution to Grade  1 is necessary prior to reintroducing study treatment .  If CB-839/placebo is 
restarted after permanent discontinuation of cabozantinib , it is also recommended that 
CB-839/placebo be permanently discontinued for a ‚â• Grade 3 recurrence of the AE that resulted 
in cabozantinib discontinuation.  Following a dose reduction of CB -839/placebo or cabozantinib, 
re-escalation to the previous dose may be allowed at the discretion of the investigator .  
11.3 Discontinuation of Treatment  
The reasons a patient may discontinue study treatment include, but are not limited to, the 
following : 
‚Ä¢ Patient no longer experiences clinical benefit as determined by the investigator. If study 
treatment is withd rawn for this reason, the date this decision is to be recorded and every 
effort should be made to continue safety evaluations, tumor assessments, and collection 
of subsequent anticancer treatment information and follow -up information for survival.  
‚Ä¢ Unaccept able side effect s the investigator feels may be due to study treatment.  
‚Ä¢ Investigator feels it is not in the best interest of the patient to continue on study.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 55  ‚Ä¢ Patient participation in another clinical study using an investigational agent or 
investigational  medical device  
‚Ä¢ Necessity for treatment with other systemic anticancer therapy (non -protocol defined)  
‚Ä¢ Necessity for withholding study drug for greater than 6 weeks (continuous) for study-
treatment related AEs  
‚Ä¢ Refusal of sexually active fertile patients to use medically accepted highly effective 
methods of contraception  
‚Ä¢ Female patient becomes pregnant 
‚Ä¢ Patient request to discontinue study treatment (with or without concurrent withdrawal of 
consent) 
‚Ä¢ Significant patient noncompliance with the protocol schedule in the opinion of the 
investigator or the Sponsor  
‚Ä¢ Sponsor request  
The Sponsor should be notified of all patient withdrawals (from study treatment or from the 
study) as soon as possible. The reason for treatment discontinuation, the date of the decision to 
discontinue treatment, and the date of the last known dose of study treatment will be recorded in 
the end-of-treatment eCRFs.  For patients who withdraw or are withdrawn from study treatment, 
the investigator should perform all End of Treatment Visit and follow up procedures as indicated 
in the schedule of study assessments ( Attachme nt 1), and continue protocol -specified evaluations 
and procedures unless consent to participate in the study is also withdrawn. All patients will be 
followed until death, unless consent to do so is specifically withdrawn by the patient or until a 
decision by the Sponsor is made to stop collection of these data.   Note that in order to maximize 
detection of progression events for the study primary endpoint patients who discontinue study 
treatment for reasons other than progressive disease  or death will continue to be followed by 
radiographic tumor imaging as described in Section 10.6.9. 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 56  In cases where the investigato r believes that a patient is clearly experiencing clinical benefit 
despite radiographic progression per RECIST 1.1, and that the potential benefit of continuing 
study treatment outweighs the potential risks, extension of study treatment beyond disease 
progression may be considered in consultation with the medical monitor. Patients who continue 
treatment beyond progression  will continue to receive all scheduled protocol assessments, 
including continued radiographic tumor assessments, until study treatment is  discontinued.  
12.0 TEST ARTICLE S/STUDY DRUG S 
12.1 Blinded Investigational Product  
CB-839 Tablets or Placebo Tablets  
Test article ( CB-839, 200 mg/tablet ) or placebo tablets that are identical in appearance will be 
administered orally . CB-839/placebo will be administered only to patients  who have signed and 
dated an Informed Consent Form. Tablets should not be cut or crushed and only administered 
whole. Doses will be administered orally on Days 1 through 2 8 of each 28-day cycle . Dosing 
will not be adjusted fo r body weight or surface area.  
The first CB -839/placebo dose of the day will be administered  in the morning  immediately after 
breakfast.  The evening/second dose should be  taken immediately after  a meal approximately 
12 hr (¬± 2 hr) after the morning dose. CB-839 ideally should be taken about 2 hr before antacid 
therapy (s ee Section 10.1.1). 
Guidelines for dose modifications are described in Section 11.1.3.  
In the rare ev ent of medical emergenc y that require s unblinding of treatment assignment , 
Investigators will have the ability to independently unblind individual patients through the IRT 
system.  Unblinding of the study treatment assignment should be reserved for situations where 
knowledge of treatment assignment is necessary for critical medical decision -making. Please 
notify the Sponsor within 1 business day  about any unblinding events. Please refer to the 
pharmacy manual for additional details  regarding this  process and procedures outlining how to 
unblind a patient  using the IRT system . 
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 57  12.2 Cabozantinib Study Drug  
Cabozantinib Tablets 
Cabozantinib (20, 40, or 60 mg/tablet s) will be administered only to patients  who have signed 
and dated an Informed Consent Form . Doses will be administered orally on Days 1 through 28 of 
each 28-day cycle . Patients should not eat for at least 2  hr before and at least 1  hr after taking 
cabozantinib , and the QD dose of cabozantinib should occur at around the same time every day , 
preferably at bedtime .  
Guidelines for dose modifications are described in  Section 11.1.3.  
12.3 Missed or Vomited Doses  
If a patient does not take a dose of CB -839/placebo within 6  hr after the scheduled time or 
cabozantinib within 12  hr after the scheduled time, he/she should be instructed to skip that dose 
and NOT to take extra study drug at their next administration. Patients should be instructed NOT 
to make up vomited doses of CB -839/placebo or cabozantinib and to report the frequency of 
vomiting occurrences associated with study drug administration to the site.   
12.4 Packaging and Labeling  
CB-839 HCl tablets (200 mg) are manufactured, packaged, and labeled according to current 
GMP. For additional information, please refer to the Pharmacy Manual.  
Placebo tablets (200 mg equivalent) are manufactured, pack aged, and labeled according to 
current GMP. For additional information, please refer to the Pharmacy Manual.  
Cabozantinib tablets are available as 20-, 40-, or 60-mg strengths. For additional information, 
please refer to the Pharmacy Manual.  
12.5 Storage and Stability  
For procedures for the proper handling, storage, preparation and administration of CB -839 
tablets or placebo tablets and cabozantinib tablets, please refer to the Pharmacy Manual.  
Patients will be requested to store all study treatment at the recommended storage conditions and 
out of reach and view of children.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 58  12.6 CB-839 Accountability, Reconciliation, and Return  
Treatment compliance will be monitored by drug accountability as well as the patient‚Äôs medical 
record and eCRF.  
On Day 1  of Cycle 1, patients will be provided with enough study treatment (CB -839/placebo 
and cabozantinib  [ex-US]) to last until their next clinic visit . Patients will return on Day 1 of 
each cycle thereafter and will receive enough supply until the next visit.  The number of  
CB-839/placebo tablets and cabozantinib tablets  remaining from the previous visit  will be 
counted and recorded  (as permitted at US sites) . 
 
The Investigator  or designee must maintain an accurate record of dispensing the study treatment  
in a drug accountability l og, a copy of wh ich must be given to the Sponsor at the end of the 
study.  
Please refer to the Pharmacy Manual for information about return or destruction of study drugs.   
12.7 Test Article /Study Drug  Compliance  
At each clinic visit, patients will be asked to return any unused  CB-839 test article / placebo 
control article  and cabozantinib  (ex-US) and will be questioned about their compliance . The 
number of remaining tablets will be recorded in a  drug accountability log.  Significant non -
compliance (missing > 60% of the study drug for reasons other than documented AE) must be 
reported to the Medical M onitor. 
13.0 Measures to Minimize/Avoid Bias  
Each patient will be assigned a unique number and will keep this number for the duration of the 
study. Patient numbers will not  be reassigned or reused for any reason.  Patients should be 
identified to the Sponsor only by their assigned number, initials, date of birth, and sex.  The 
Investigator must maintain a patient master log .  
14.0 STATISTICAL ANALYSIS  
This section outlines the stat istical analysis strategy and procedures for the study.  Additional 
details of the primary and key secondary analyses will be provided in the Statistical Analysis 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 59  Plan (SAP).  If, after the study has begun but prior to the final analysis, important changes are 
made to the protocol that affect principal features of the primary or key secondary analyses, the 
protocol and/or SAP will be amended, as appropriate.    
14.1 General Study Design  
This is a multicenter, randomized , double-blind, placebo -controlled  Phase 2 study comparing 
two treatment regimens for patients with advanced or metastatic  ccRCC. Patients will be 
randomized to either CB -839 with cabozantinib or placebo with cabozantinib in a 1:1 ratio. The 
primary endpoint of this Phase  2 study is IRC-adjudicated PFS. The key secondary endpoint is 
OS. Patients will be stratified by: a) prior PD -1/PD-L1 inhibitor therapy (yes vs. no) and b) 
IMDC Prognostic Risk Group (favorable vs. intermediate  vs. poor; Attachment  3). 
14.2 Independent Radiology Committee (IRC)  
An IRC will be established to evaluate tumor scans and relevant history data of trial patients in a 
central, blinded, and independent fashion.  The IRC will comprise board -certified radiologists 
who will use RECIST 1.1 to a ssess radiographic disease response and progression following 
randomization. The IRC will evaluate study data at designated interim (if applicable) and final 
analyses. Additional details regarding IRC member qualification, training, methods, procedures, 
and other issues relevant to committee operations will be described in the IRC Charter.   
14.3 Independent Data M onitoring Committee  
An Independent Data Monitoring Committee (IDMC) will be established to monitor the safety 
and progress of the study on a regular basis. The committee will operate independently from the 
Sponsor and the clinical investigators.  To minimize the potential introduction of bias, these 
individuals will not have any direct contact with the study site personnel or patients.  IDMC 
members will  be selected fo r their expertise in oncology. The IDMC will convene periodically 
and the start date will depend on patient accrual rates. Details of the composition, role, 
responsibilities, operational considerations, and trial stopping guidelines will be provided in the 
IDMC Charter.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 60  14.4 Study Steering Committee  
A study steering committee will comprise study investigators who are experts in the treatment of 
RCC who will provide ongoing guidance on issues including protocol design, implementation 
and interpret ation of clinical study results.  The steering committee duties and obl igations will be 
outlined in the Study Steering Committee C harter.   
14.5 Analysis Patient Sets  
14.5.1 Efficacy Analysis Patient Set 
The ITT patient set will be the basis for the primary efficacy an alysis for this study.  The ITT 
patient set is composed of all randomized patients. Patients in the ITT set will be analyzed for 
treatment efficacy according to the treatment group to which they are randomized, regardless of 
post-randomization protocol devi ations, including no protocol treatment received . 
14.5.2 Safety Analysis Set  
All patients who receive any study -specific treatment (CB -839/ placebo or cabozantinib ) after 
randomization will be included in the analysis of safety and analyzed according to the actual 
treatment received.  Patients having taken any CB -839 tablet will be analyzed in the CB -839 with 
cabozantinib combination arm.   
14.6 Efficacy Analysis  
14.6.1 Primary Efficacy Endpoint: IRC -Adjudicated PFS  
The primary efficacy endpoint is PFS defined as the time from randomization to the earlier of 
IRC-adjudicated disease progression or death due to any cause.  Radiographic disease progression 
will be assessed using the RECIST  v.1.1 criteria.  If the disease progression assessment involves 
more than one date, the ea rliest date will be used as the event date.  The duration of PFS will be 
censored at the date of the last evaluable radiographic disease assessment prior to the occurrence 
of any of the following scenarios : 
ÔÇ∑ Patient is alive and progression free at the time of analysis data cutoff  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 61  ÔÇ∑ Disease progression  or death occurs after data are missing for two consecutive scheduled 
radiographic disease assessments , including [a] missing assessments, [b] insufficient  data 
for the assessments, or [c] assessments  resulting in a non -evaluable status for overall 
response per RECIST 1.1 . 
ÔÇ∑ Prior to documentation of disease progression  or death, patient receives non -protocol 
anticancer  therapy, or any other treatment that in the opinion of the IRC interferes with 
assessment of disease per RECIST  1.1 (this includes the scenario when the IRC disagrees 
with the Investigator -judged progressive disease status but the patient  received 
subsequent anticancer therapy). 
Patients missing baseline radiographic disease assessment will be censored at the date of 
randomization  (i.e., PFS duration will be 0 ). 
The primary inferential PFS comparison between the two treatment arms will take place when a 
total of 262 events have been observed.  Assuming exponential PFS distributions, patient accrual 
over a period of 1 5 months, a median PFS of 8 months for the control arm and a hazard ratio of 
0.69 in favor of the experimental arm  (equivalent to a 45% increase of median PFS to 11.6 
months for the experimental arm) , it is estimated that a total of 262 PFS events will occur with 
7 months of additional follow -up after accrual completion.  The primary analysis will use the 
stratified log -rank test with the randomization stratification factors of prior PD-1/PD-L1 inhibitor 
therapy (yes vs. no) and IMD C Prognostic Risk Group (favorable vs. intermediate vs. poor).  A 
2-sided p < 0.05 in favor of the CB -839 + cabozantinib experimental treatment will be regarded 
as a positive result for the study . The experimental over control hazard ratio will be estimated  by 
a stratified Cox proportional hazards model with the same randomization stratification factors . 
Kaplan-Meier curves will be presented with median estimates to visually display the progression 
free survival percentages .  In addition, as a secondary anal ysis for the primary endpoint, the 
above analyses will be repeated with only two levels, i.e. favorable vs. intermediate /poor, for the 
IMDC Prognostic Risk grouping.   
14.6.2 Secondary Efficacy Endpoints  
Overall Survival (OS)  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 62  OS is defined as the time from randomization to death due to any cause.  For patients alive at the 
time of analysis, OS will be censored at the time when the patient is last known to be alive.  OS 
analyses will be the similar to the PFS analyses.  
14.6.3 Additional Endpoints 
Overall Response Rate (ORR)  
ORR is defined as the percentage of patients with CR or PR according to the RECIST 1.1 
criteria. Response will be adjudicated by the IRC , and response confirmation is not required to 
compare the two arms in this double -blind protocol.   Patients with no evaluable on-study 
response assessments will be regarded as non -responders.  The ORR will be compared between 
treatment arms by both the Fisher‚Äôs exact test and a logistic regression analysis accounting for 
the randomization  stratification factors.  
Duration of Response (DOR)  
For patients achieving a PR or a CR, the duration of response will be calculated as the time 
between the first documentation of a PR or a CR to the first documentation of PD or death, 
whichever occurs fir st. For patients achieving first a PR then a CR, the PR date will be the 
starting date for response duration calculation.  For responders for whom a PD has not been 
documented yet,  Section 14.6.1 conventions regarding P FS censoring will apply.  Response 
duration will be descriptively presented for responders in each treatment arm.  
Disease Control Rate  (DCR) 
DCR is defined as the summed percentage of patients with CR, PR or SD documented at least 8 
weeks (-5 day window) following randomization according to RECIST  v1.1 criteria.  
Patient Reported Outcomes  
Patients will be assessed using the NCCN -Functional Assessme nt of Cancer Therapy (FACT)  
Kidney Symptom Index ( FKSI-19) questionnaire and the EuroQoL 5D utility score ( EQ-5D-5L) 
and compared between the two treatment arms . Details of the planned analyses for these 
outcomes will be provided in the SAP . 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 63  14.6.4 Exploratory  Analyses  
To explore the effects of the following baseline factors, a multivariate , stratified  Cox model 
regression analysis will be conducted for PFS.  The model will be stratified  by the randomization 
stratification factors and include treatment arm as an independent variable , with the following 
variables as additional covariates:   
ÔÇ∑ Race (Caucasian vs. all others)  
ÔÇ∑ Sex (male vs. female) 
ÔÇ∑ Age (18‚Äì65 vs. > 65 years)  
ÔÇ∑ Number of previous anti-angiogenic therapies ( 1 vs. >1)  
The same analyses will be repeated with only two levels, i.e. favorable vs. intermediate/poor, for 
the IMDC Prognostic Risk grouping.  
Univariate plots will also be presented for descriptive purposes.   
14.7 Safety Analysis  
Safety wi ll be assessed by the patient incidence and severity of treatment -emergent adverse 
events (TE AEs).  TEAEs are adverse events (AEs) not present prior to protocol treatment, or an 
already present event that worsens either in intensity or frequency during or following protocol 
treatment  initiation.  The analysis will be performed on the Safety Analysis Patient Set as defined 
in Section 14.5.2.  
TEAEs will be coded by System Organ Class  and Preferred Term  using the Medical Dictionary 
for Regulatory Activities (MedDRA).  The number and proportion of patients reporting a given 
TEAE will be tabulated by treatment group according to the worst severity  reported. Separate 
tables will be constructed for a) all reported TEAEs, b) serious TE AEs, and c) TEAEs leading to 
permanent discontinuation of study treatment.  The above tables will also be presented for TEAEs 
judged to be related (probably or possibilit y) to the study treatment.  
14.8 Sample Size Estimation  
The sample size of 416 patients, randomized 1:1 for CB -839 + cabozantinib vs. placebo + 
cabozantinib, is anticipated to provide sufficient efficacy data to demonstrate a clinically and 
statistically significant benefit for CB -839. For the purposes of study design , it is assumed  that 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 64  the control arm's true median PFS will be approximately 8 months based upon recently published 
randomized Phase 3 study results with cabozantinib monotherapy  (Choueiri 2015), and that the 
true hazard ratio (HR) favoring CB -839 + cabozantinib over placebo + cabozantinib will be 0.6 9, 
corresponding to a clinically significant increase of 45% or 3.6 months from 8 months to 
11.6 months.  
The proposed study will enroll patients with an accrual period of 1 5 months and additional 
follow-up of 7 months. If the control arm's median PFS is 8  months and the true PFS HR of 
experimental patients to control patients is 0.6 9, the study will require approximately 
208 experimental patients and 208 control patients in order to reject the null hypothesis of equal 
PFS between the two treatment arms with a power of 0.8 5.  This estimation assumes a 2 -sided 
type I error rate of 0.05, uniform accrual, exponential PFS distr ibutions and the log -rank test for 
PFS comparison.  The expected total PFS event count is 262 under the above assumptions.  
15.0 Adverse Events  
15.1 Definitions  
An adverse event  (AE) is any untoward, undesired, or unplanned event in the form of signs, 
symptoms, diseas e, or laboratory or physiologic observations occurring in a person given a test 
article or associated with other protocol interventions  in a clinical study.  The event does not need 
to be causally related to the test article.  An AE includes, but is not limi ted to, the following:  
ÔÇ∑ Any AE not previously observed in the patient that emerges during the protocol 
specified AE reporting period  
ÔÇ∑ Any clinically significant worsening of a preexisting condition  
ÔÇ∑ Complications occurring as a result of protocol -mandated int erventions (e.g. , invasive 
procedure such as biopsies), including in the period prior to receiving the first dose of 
the test article that are related to the protocol -mandated intervention  (e.g., medication 
wash out, biopsies)  
ÔÇ∑ An AE occurring from overdose  (i.e., a dose higher than that indicated in the 
protocol) of a test article, whether accidental or intentional  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 65  ÔÇ∑ An AE occurring from abuse (e .g., use for nonclinical reasons) of a test article  
ÔÇ∑ An AE that has been associated with the discontinuation of the use of a test article  
Any treatment -emergent abnormal laboratory result which is clinically significant, i.e., meeting 
one or more of the following conditions, should be recorded as a single diagnosis on the adverse 
event page in the eCRF: 
ÔÇ∑ Accompanied by c linical symptoms  
ÔÇ∑ Leading to a change in study medication ( e.g., dose modification, interruption , or 
permanent discontinuation)  
ÔÇ∑ Requiring a change in concomitant therapy ( e.g., addition of, interruption of, 
discontinuation of, or any other change in a conco mitant medication, therapy or 
treatment)  
A serious adverse event  (SAE) is an AE that:  
ÔÇ∑ Results in death (NOTE : death is an outcome, not an event)  
ÔÇ∑ Is life-threatening   
ÔÇ∑ Requires inpatient hospitalization or prolongation of an existing hospitalization  
ÔÇ∑ Results in a persistent or significant disability or incapacity  
ÔÇ∑ Results in a congenital anomaly or birth defect  
ÔÇ∑ Additionally, important medical events that may not result in death, be life -
threatening, or require hospitalization may be considered SAEs when, based on 
appropriate medical judgment, they may jeopardize the patient and may require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition.  Examples of such events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 66  Clear progression of neoplasia should not be reported as an AE or SAE (unless the 
investigator considers the progression of underlying neoplasia to be atypical in its nature, 
presentation or severity  from the normal course of the disease in a particular patient ). Findings that 
are clearly consistent with the expected progression of the underlying ca ncer should not be 
reported as an adverse event, and hospitalizations due to the progression of cancer do not 
necessarily qualify for an SAE.  In contrast, a ll deaths including those related to progression of 
disease and sudden and unexplained death should  be reported as an SAE.  If there is any 
uncertainty about a finding being due solely to progression of neoplasia, the finding should be 
reported as an AE or SAE as appropriate.  
Life-threatening , in the context of an SAE, refers to immediate risk of death  as the event 
occurred per the reporter.  A life-threatening experience does not include an experience, had it 
occurred in a more severe form, which might have caused death, but as it actually occurred, did 
not create an immediate risk of death.  For example, hepatitis that resolved without evidence of 
hepatic failure would not be considered life -threatening, even though hepatitis of a more severe 
nature can be fatal.  Similarly, an allergic reaction resulting in angioedema of the face would not 
be life-threatening, even though angioedema of the larynx, allergic bronchospasm, or 
anaphylaxis can be fatal.  
Hospitalization  is official admission to a hospital.  Hospitalization or prolongation of a 
hospitalization constitutes criteria for an AE to be serious; however, it is not in itself considered 
an SAE. In the absence of an AE, a hospitalization or prolongation of a hospitalization should 
not be reported as an SAE.  This is the case in the following situations:  
ÔÇ∑ The hospitalization or prolongation of hospitalization is  needed for a procedure required 
by the protocol.  Day or night survey visits for biopsy or surgery required by the protocol 
are not considered serious.  
ÔÇ∑ The hospitalization or prolongation of hospitalization is part of a routine procedure 
followed by the ce nter (e.g., stent removal after surgery).  This should be recorded in the 
study file.  
ÔÇ∑ Hospitalization for survey visits or annual physicals falls in to the same category.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 67  In addition, hospitalizations planned before the start of the study, for a preexisting condition that 
has not worsened, do not constitute an SAE.  Visits to the Emergency Room that do not result in 
hospital admission are not considered hospitalizations , but may constitute a medically important 
event. 
Disability  is defined as a substantial dis ruption in a person‚Äôs ability to conduct normal life 
functions.  
If there is any doubt about whether the information constitutes an SAE, the information is treated 
as an SAE.  
Causality Attribution Guidance:  
Adverse event s should be considered ( probably or p ossibly) treatment -related, unless they fulfill 
the following criteria  (in which circumstances it should be considered unlikely related or 
unrelated):  
ÔÇ∑ Evidence exists that the AE has an etiology other than the investigational product (e.g. , 
preexisting med ical condition, underlying disease, intercurrent illness , or concomitant 
medication), and/or  
ÔÇ∑ The AE has no plausible temporal relationship to administration of the investigational 
product (e.g., a new cancer diagnosed 2 days after first dose of study drug) . 
Relatedness  to study medication will be graded as either , ‚Äúprobably‚Äù, ‚Äúpossibly‚Äù, ‚Äúunlikely‚Äù,  or 
‚Äúunrelated‚Äù as follows:  
Probably  Related ‚Äì The adverse event  
ÔÇ∑ Follows a reasonable temporal sequence from drug administration  
ÔÇ∑ Abates upon discontinuation of the drug 
ÔÇ∑ Cannot be reasonably explained by the known characteristics of the patient‚Äôs clinical 
state 
Possibly Related ‚Äì The adverse event  
ÔÇ∑ Follows a reasonable temporal sequence from drug administration  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 68  ÔÇ∑ Could have been produced by the patient‚Äôs clinical sta te or by other modes of therapy 
administered to the patient  
Unlikely Related  - The adverse event  
ÔÇ∑ Is most likely  to be explained by the patient‚Äôs clinical state or by other modes of therapy 
administered to the patient  
Unrelated ‚Äì The adverse event  
ÔÇ∑ Does not follow a reasonable sequence from drug administration  
ÔÇ∑ Is readily explained by and considered by the Principal Investigator to be an expected 
complication of the patient‚Äôs primary malignancy, clinical state , concurrent medical 
conditions , or by other modes of therapy administered to the patient  
A protocol-related adverse event  is an AE occurring during a clinical study that is not related 
to the test article, but is considered by the Investigator or the Medical Monitor (or designee) to be 
related to the rese arch conditions, i .e., related to the fact that a patient is participating in the 
study. For example, a protocol -related AE may be an untoward event occurring during a washout 
period or an event related to a medical procedure required by the protocol.  
Other Reportable Information : certain events, although not considered an SAE, must be 
recorded, reported, and followed up within the same timelines as for an SAE.  These events  
include: 
ÔÇ∑ A case involving a pregnancy exposure to a test article, unless the product  is indicated for 
use during pregnancy e .g., prenatal vitamins.  Information about use in pregnancy 
encompasses the entire course of pregnancy and delivery and perinatal and neonatal 
outcomes, even if there were no abnormal findings.  If a pregnancy is confi rmed, test 
article must be discontinued immediately.  All reports of pregnancy must be followed for 
information about the course of the pregnancy and delivery, as well as the condition of 
the newborn.  When the newborn is healthy, additional follow -up is not needed. 
Pregnancies occurring up to 6 mo nths after completion of the study treatment must also 
be reported to the Investigator.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 69  ÔÇ∑ Overdose  and abuse (e.g., a dose higher than that indicated in the protocol) with or 
without an AE . Overdose and/or abuse are n ot considered SAEs , but should be reported 
to the Sponsor expeditiously (within 24 hours of awareness) . Overdose and/or abuse 
should be recorded as an AE in the eCRF and reported to Safety as a non -serious Grade 1 
AE using the SAE Report form (by checking the ‚Äúnot applicable‚Äù box in the seriousness 
criterion). If the overdose and/or abuse is/are a ssociated with  the following : 
o An AE: both the term overdose or abuse and the associated AE should be 
recorded in the eCRF as AEs  
o SAE: the term overdose or abuse should continue to be recorded as  a non-serious 
AE in both the eCRF and the SAE report form . In addition, an SAE associated 
with the overdose/abuse should be reported as an SAE in the SAE Report Form.  
15.2 Recording and Reporting  
After informed consent, but prior to initiation of study drug , only SAEs caused by protocol - 
mandated interventions (e.g., a protocol-required blood test ) will be collected . 
Patients will be followed for AEs or SAEs from the time the patient initiates tre atment with the 
study regimen through at least  28 days after the last dose  of all  study treatment s (CB-
839/placebo and cabozantinib) , or until initiation of a new anticancer therapy (if earlier). The 
Investigator must follow  up on all drug -related AEs, SAEs, and other reportable information 
until the events have subsided, returned to baseline, the patient has initiated any other anticancer 
therapy, or in case of permanent impairment, until the condition stabilizes.  
All AEs and SAEs must be recorded on  source documents  and collected in EDC system. 
Although AEs should be based on the signs or symptoms detected during the physical 
examination and on clinical evaluation of the patient , a specific diagnosis should be reported as 
the AE whenever feasible . In addition to the information obtained from those sources, the patient 
should be asked the following nonspecific question : ‚ÄúHow have you been feeling since your last 
visit?‚Äù Signs and symptoms should be recorded using standard medical terminology.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 70  Any unant icipated risks to the patients must be reported by the investigator promptly to the 
Sponsor and IRB/IEC.  
15.3 Serious Adverse Event Reporting  
All SAEs  regardless of attribution, other reportable information, and follow -up information  must 
be reported within 24 hr of learning of the event by  completing the SAE form and either 
emailing or faxing the form to the SAE Reporting Contact . Calithera Biosciences  (or designee) 
will process and evaluate all SAEs as soon as the reports are received.  For each SAE received, 
Calithera Biosciences  will make a determination as to whether the criteria for expedited 
reporting have been met.  The Medical Monitor should also be contacted for any fatal or life -
threatening SAE that is considered possibly or probably related to study drug.  
Calithera Biosciences, Inc.  (or designee) is responsible for reporting relevant SAEs to the 
relevant regulatory authorities and participating Investigators, in accordance with FDA 
regulations 21 CFR 312.32, ICH Guidelines, European Clinical Trials Directive (Directive 
2001/20/EC) , and/or local regulatory requirements  and monitoring the safety profile of the study 
drug. To meet this requirement, Calithera Biosciences, Inc.  (or designee) may request additional 
information from the sites including , but not limited to, hospitalization records . Any requests for 
such information should be addressed in a timely manner. Additionally, any SAE considered b y 
an Investigator to be possibly  or probably related to the study therapy that is brought to the 
attention of the Investigator at any time outside of the time period specified for SAE reporting  
also must be reported immediately to one of the individuals li sted on the Sponsor contact  
information page.  
Reporting of SAEs by the Investigator to the IRB /IEC will be done in accordance with the 
standard operation procedures and policies of the IRB/ IEC. Adequate documentation must be 
maintained showing that the IRB/ IEC was properly notified.   
PrimeVigilance, the pharmacovigilance vendor, has been contracted to provide drug safety and 
pharmacovigilance support, including EudraVigilance management and distribution of SUSAR 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 71  reports, in re lation to CB -839 investigational medicinal product (IMP) clinical development 
program by Calithera Biosciences Inc.  
16.0 STUDY SUSPENSION, TERMINATION, AND COMPLETION  
The Sponsor may suspend or terminate the study or any part of the study at any time for any 
reason. If the Investigator suspends or terminates the study, the Investigator will promptly inform 
the Sponsor and the IRB/IEC and provide a detailed written explanation.  The Investigator will 
also return all CB-839 test articles, containers, and other stud y materials to the Sponsor  or 
designee, or destroy the materials at the investigative site.  Upon study completion, the 
Investigator will provide the Sponsor, IRB/IEC, and regulatory agency with final reports and 
summaries as required by regulations.  
17.0 INFORM ED CONSENT  
The Investigator will provide for the protection of the patients by following all applicable 
regulations.  These regulations are available upon request from the Sponsor.  The Informed 
Consent Form used during the informed consent process must be r eviewed by the Sponsor and 
approved by the IRB/IEC.  
Before any procedures specified in the protocol are performed, a patient must:  
ÔÇ∑ Be informed of all pertinent aspects of the study and all elements of informed consent  
ÔÇ∑ Be given time to ask questions and time to consider the decision to participate  
ÔÇ∑ Voluntarily agree to participate in the study  
ÔÇ∑ Sign and date an IRB/IEC approved Informed Consent Form 
18.0 PROTOCOL AMENDMENTS  
Any significant change in the study requires a protocol amendment.  An Investigator must not 
make any changes to the study without IRB/IEC and Sponsor approval . All protocol amendments 
must be reviewed and approved following the same process as the original protocol.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 72  19.0 QUALITY CONTROL AND ASSURANCE  
The Sponsor or designee performs quality contro l and assurance checks on all clinical studies 
that it sponsors.  Before enrolling any patients in this study, Sponsor personnel and the 
Investigator review the protocol, the Investigator‚Äôs Brochure, the eCRFs and instructions for 
their completion, the proc edure for obtaining informed consent, and the procedure for reporting 
AEs and SAEs.  A qualified representative of the Sponsor will monitor the conduct of the study.  
During these site visits, information recorded in the eCRFs is verified against source docu ments.  
20.0 DIRECT ACCESS, DATA HANDLING, AND RECORD  KEEPING  
20.1 Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
ÔÇ∑ Consensus ethical principles derived from international guidelines including the 
Declaratio n of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines  
ÔÇ∑ Applicable ICH Good Clinical Practice (GCP) Guidelines  
ÔÇ∑ Applicable laws and regulations  
ÔÇ∑ The investigator will be responsible for the follo wing: 
‚Äì Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC  
‚Äì Notifying the IRB/IEC of SAEs or other significant safety findi ngs as required by 
IRB/IEC procedures  
‚Äì Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations  
20.2 Investigator  
The Investigator will permit study -related monitoring, audits, IRB/IEC review, and regulatory 
inspections by providing direct access to source data and documents.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 73  All study-related information will be recorded on s ource documents.  All required data will be 
recorded in the eCRFs. All eCRF data must be submitted to the Sponsor throughout and at the 
end of the study.  
If an Investigator retires, relocates, or otherwise withdraws from conducting the study, the 
Investigator must notify the Sponsor to agree upon an acceptable storage solution.  Regulatory 
agencies will be notified with the appropriate documentation.  
All study-related laboratory and clinical data gathered in this protocol will be stored in a 
password -protected database.  All patient information will be handled using an onymous 
identifiers.  Linkage to patients‚Äô study data  is only possible after accessing a password -protected 
database. Access to the database is only available to individuals directly involved in the study.  
Patient personal health information that is accessed for this study will not be reused or disclosed 
to any other person or entity, or for other research.  
20.3 Sponsor 
The data will be checked for completeness and correctness in real -time online.  
Data are checked as they are entered into the EDC system. Off-line checks will also be run to 
assess the n eed for additional data review.  
20.4 Pre-Study Documentation  
The Investigator must provide the Sponsor with the following documents BEFORE enrolling any 
patients: 
ÔÇ∑ Completed and signed form 1572  or (for sites outside the US) ICH GCP Statement  
ÔÇ∑ All applicable country -specific regulatory forms  
ÔÇ∑ Current, dated curricula vitae for the Investigator, Sub-Investigators, and other 
individuals having significant investigato r responsibility who are listed on the Form 1572 
or equivalent, or the clinical study information form.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 74  ÔÇ∑ Copy of the IRB/IEC  approval letter for the protocol and informed consent.  All 
advertising, recruitment, and other written information provided to the p atient must be 
approved by the IRB/IEC.  Written assurance of continuing approval (at least annually) as 
well as a copy of the annual progress report submitted to the IRB/IEC must also be 
provided to the Sponsor.   
ÔÇ∑ Copy of the IRB/IEC -approved Informed Consent Form to be used  
ÔÇ∑ Where applicable, a list of the IRB/IEC members or a Federal-Wide Assurance/ 
Department of Health and Human Services ( FWA/DHHS ) number 
ÔÇ∑ Copy of the protocol sign -off page signed by the Investigator  
ÔÇ∑ Copy of the current medical license  (online verification is also acceptable)  of the 
Principal Investigator, any Sub-Investigators  and any other individuals having significant 
responsibility as listed in the 1572  (or equivalent ) 
ÔÇ∑ Fully executed Clinical Trial Agreement  (CTA), if applicable  
ÔÇ∑ Financial disclosure form  for the Principal Investigator and any other persons listed in the 
1572 (or equivalent)  
ÔÇ∑ A written document containing the name, location, certification number, and date of 
certification of the laboratory to be used for laboratory a ssays and those of other facilities 
conducting tests.  This document should be returned along with the 1572 (or equivalent) . 
The Sponsor must be notified if the laboratory is changed or if any additional laboratory 
is to be used.  
 
20.5 Records Retention  
The Investigator shall retain and preserve one copy of all data generated in the course of the 
study, specifically including but not limited to those defined by GCP as essential, for the longer 
of: (i) 2 years after the last marketing authorization for the study d rug has been approved or the 
Sponsor has discontinued its research with respect to such drug or (ii) such longer period as 
required by applicable global regulatory requirements.  At the end of such period, the Investigator 
shall notify the Sponsor in writin g of its intent to destroy all such material.  The Sponsor shall 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTI AL 75  have 30 days to respond to the Investigator‚Äôs notice, and the Sponsor shall have a further 
opportunity to retain such materials at the Sponsor‚Äôs expense.   
21.0 PUBLICATION AND AUTHORSHIP  
Results of the study, regardless of outcome, will be submitted for publication in peer -reviewed 
congresses and/or scientific journals. Per the International Committee of Medical Journal Editors 
(ICMJE) recommendations, an author is generally considered to be anyone who provides 
substantive intellectual contributions to a published study.  Specifically, authorship credit should 
be based on 1) substantial contributions to study  conception and design, or acquisition, analysis 
and interpretation of data, and 2) drafting the article or revising it critically for important 
intellectual content, 3) final approval of the version to be published, and 4) agreement to be 
accountable for all aspects of the work to ensure its accuracy and integrity.  All four conditions 
should be met.
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  76  22.0 LIST OF ABBREVIATION S 
Abbreviation or Term1 Definition/Explanation  
AE Adverse event  
ALT Alanine aminotransferase  
aPTT Activated partial thromboplastin time  
AST Aspartate aminotransferase  
BID Twice daily  
C1D1 Cycle 1 Day 1  
CB-Cabo CB-839 plus cabozantinib combination treatment  
Ccr Creatinine Clearance  
ccRCC Clear Cell Renal Cell Carcinoma  
CFR Code of Federal Regulations  
Cmax Maximum observed concentration  
CNS Central nervous system  
CR Complete re sponse 
CTA Clinical Trial Agreement  
CT Computed tomography  
CTCAE Common Terminology Criteria for Adverse Events  
CYP Cytochrome P450  
DCR Disease Control Rate  
DICOM Digital Imaging and Communications in Medicine  
DLT Dose Limiting Toxicity  
DOR Duration of Response  
ECG Electrocardiogram  
eCRF Electronic Case Report Form  
EDC Electronic data capture  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
GI Gastrointestinal  
GLP Good Laboratory Practice  
GLS Glutaminase  
GMP Good Manufacturing Practice  
HIV Human immunodeficiency virus  
HR Hazard ratio  
IC50 Half maximal inhibitory concentration  
IDMC Independent Data Monitoring Committee  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  77  Abbreviation or Term1 Definition/Explanation  
IEC Independent Ethics Committee  
IMDC International Metastatic Renal Cell Carcinoma Database  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRC Independent R adiology Committee  
IRT Interactive Response Technology  
ITT Intent-to-treat 
IV Intravenous  
KPS Karnofsky Performance Score  
LC-MS/MS Liquid chromatography -mass spectrometry/mass spectrometry  
LDH Lactate dehydrogenase  
LFT Liver Function Test  
LMWH Low molecular weight heparins  
MedDRA  Medical Dictionary for Drug Regulatory Activities  
mRCC Metastatic Renal Cell Carcinoma  
MRI Magnetic Resonance Imaging  
ORR Overall response rate  
OS Overall Survival  
Pbo-Cabo Placebo tablets plus cabozantinib treatment  
PD-1 Programmed Cell Death protein 1  
PD-L1 Programmed Death Ligand 1  
PFS Progression Free Survival  
PK Pharmacokinetic(s)  
PPI Proton Pump Inhibitors  
PR Partial response  
PSA Prostate Specific Antigen  
PT Prothrombin time  
QD Once daily  
QoL Quality of life  
QTc Corrected QT interval  
RP2D Recommended Phase 2 Dose  
RCC Renal cell carcinoma  
RECIST Response  Evaluation Criteria in Solid Tumors  
SAE Serious adverse event  
SAP Statistical analysis plan  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  78  Abbreviation or Term1 Definition/Explanation  
SD Stable disease  
TKI Tyrosine kinase inhibitor  
TID Three times daily  
TNBC Triple negative breast cancer  
TSH Thyroid stimulating hormone  
ULN Upper limit of  normal 
US United States  
VEGF Vascular Endothelial Growth Factor  
 
23.0 REFERENCES  
Calithera Biosciences, Inc. CB -839 Investigator‚Äôs Brochure  
Chou TC and Talalay P. Quantitative analysis of dose -effect relationships: the combined effects 
of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation. Feb 1984:27 -55. 
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib 
versus everolimus in advanced renal -cell carcinoma.  N Engl J Med  2015;373:1814 -1823. 
 
Choueiri TK, Escudier BJ, Powles T, Tannir NM, Mainwaring P, Rini BI, et al.  Cabozantinib 
versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, 
open-label, phase 3 trial. Lancet Oncol  2016;17:917.  
Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, et al. Cabozantinib 
versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk 
(Alliance A031203 CABOSUN randomised trial): Progression -free survival by in dependent 
review and overall survival update . Eur J Cancer  2018;94: 115 ‚Äì125. 
Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy 
testing in clinical trials. Sep 2014. Accessed at 
http://www.hma.eu/fileadmin/dateien/Hum an_Medicines/01 -
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf  
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 
2009;45:228 -247. 
Escudier B, et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v 
sunitinib (S) for treatment -na√Øve advanced or metastatic renal cell carcinoma (mRCC), including 
IMDC risk and PD -L1 expression subgroups. Europe an Society of Molecular Oncology 2017.  
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  79  Gross MI, Demo SD, Dennison JB, Chen L, Chernov -Rogan T, Goyal B, et al. Antitumor 
activity of the glutaminase inhibitor CB -839 in triple -negative breast cancer. Mol Cancer  
Ther 2014;13:890 -901.  
 
Heng DYC, Xie W, Re gan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors 
for overall survival in patients with metastatic renal cell carcinoma treated with vascular 
endothelial growth factor ‚Äìtargeted agents: Results from a large, multicenter study. J Clin Oncol  
2009;27:5794 -5799. 
 
Heng DYC, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al.  
External validation and comparison with other models of the International Metastatic Renal -Cell 
Carcinoma Database Consortium prognostic model: a population -based study. Lancet Oncol  
2013;14:141 ‚Äì148. 
 
Hsieh JJ, Purdue MP, Signoretti S, et al. Renal Cell Carcinoma. Nature Reviews Disease Primers  
2017;3:1-19. 
 
ICMJE guidelines (2015) Recommendations for the Conduct, Reporting, Editing, and  
Publication  of Scholarly Work in Medical Journals. Retrieved from http://www.icmje.org/icmje -
recommendations.pdf  
 
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, et al.  International Metastatic Renal Cell 
Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell 
carcinoma previously treated with first -line targeted therapy: A population -based study.  Lancet 
Oncol 2015;16:293 -300. 
 
 
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al, Nivolumab 
versus everolimus in advanced renal -cell carcinoma. N Engl J Med  2015;373:1803 -1813. 
 
 
Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyro sine 
kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol.  
2009;6:219 -28. 
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
 
CONFIDENTIAL   82  12 PK samples are collected  on C2D1: pre-dose and 2 hr post dose, and on C3D1: 4 hr and 6 hr post dose.  Refer to the laboratory manual for  detailed instructions on samples kits, 
 collection, and shipment to a central laboratory. Contact Sponsor for guidance on options for collecting missed samples.  
13 Optional tumor biopsies  to be collected as clinically indicated from patients at North American sites only.  
14 Screening tumor assessments within 28 days prior to randomization accepted. Radiographic assessments should include brain MRI  for patients with history of brain metastases or 
 suggestive sym ptoms and bone scan (bone scintigraphy) for patients with history of bone metastases or suggestive symptoms.  
15 Radiographic t umor assessments  and QoL questionnaires will be performed a t the scheduled  intervals relative to the date of C1D1 regardless of study treatment holds or delays  
(note that treatment cycles are fixed and do not shift  as a result of dose interruptions) . 
16 Unless performed within the previous 4  weeks (Note: patients who discontinue  study treatment for reasons other than pro gressive di sease [PD] or death will continue to be 
 followed by radiographic  tumor imaging until documentation of radiographic PD per RECIST v.1.1, death, initiation of a new anti cancer therapy, or withdrawal of consent .) 
17 Patients will be contacted every 3 mo for the first 1 2 mo afterdiscontinuation  of all study treatment s (CB-839/placebo and cabozantinib)  and every 6 mo thereafter for survival 
follow-up. 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  83  ATTACHMENT 2: CLINICAL LABORATORY TESTS  
Hematology  (Peripheral Blood Sample) : 
ÔÇ∑ Hemoglobin  
ÔÇ∑ Hematocrit  
ÔÇ∑ Red blood cell count 
ÔÇ∑ White blood cell count with differential  
ÔÇ∑ Platelet count  
Coagulation Tests  
ÔÇ∑ PT, aPTT and INR  
Serum Chemistry -Full Metabolic Panel  (Peripheral Blood Sample)  with additional analytes  
ÔÇ∑ Phosphate  
ÔÇ∑ Magnesium  
ÔÇ∑ Sodium 
ÔÇ∑ Potassium  
ÔÇ∑ Chloride 
ÔÇ∑ CO2  
ÔÇ∑ Calcium 
ÔÇ∑ Glucose 
ÔÇ∑ Blood urea nitrogen2 ÔÇ∑ Total protein  
ÔÇ∑ Albumin 
ÔÇ∑ Total and direct bilirubin1 
ÔÇ∑ Aspartate aminotransferase (AST)  
ÔÇ∑ Alanine aminotransferase (ALT)  
ÔÇ∑ Alkaline phosphatase (A LP) 
ÔÇ∑ Lactate dehydrogenase (LDH)  
ÔÇ∑ Creatinine  
1 Direct bilirubin is only required if Total Bilirubin is above the upper limit of normal .  
2 Some sites, particularly in Europe, routinely measure blood urea instead of blood urea nitrogen in the 
standard of care chemistry panel. Because blood urea nitrogen and blood urea labs serve the same purpose 
and are interconvertible, either test is acceptable per protocol. The EDC system will allow for either blood 
urea nitrogen or urea levels to be collected.  
 
Thyroid fun ction test s 
ÔÇ∑ TSH  
ÔÇ∑ Free T4 (required at screening; after screening only i f TSH is outside normal range)  
 
Pregnancy test ( urine or serum ÔÅ¢-HCG): Women of child -bearing potential  
Urinalysis  
Screening:  
ÔÇ∑ Protein ÔÇ∑ Leukocyte esterase  
ÔÇ∑ pH 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  84  ÔÇ∑ Glucose 
ÔÇ∑ Ketones 
ÔÇ∑ Hemoglobi n 
ÔÇ∑ Nitrite 
ÔÇ∑ Urine protein:creatinine ratio 
(UPCR) or 24 -hour urine protein  
 
Post-Screening : 
ÔÇ∑ Protein (to monitor for 
proteinuria; dipstick acceptable 
and if positive will be followed 
by UPCR)  
 
 ÔÇ∑ Specific gravity  
ÔÇ∑ Urobilinogen  
 
ÔÇ∑ Microscopic evaluation  performed at the 
discretion of the Investigator based on 
results of routine urinalysis or as clinically 
indicated 
 
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  85  ATTACHMENT 3: IMDC PROGNOSTIC MODEL  
Source: Heng 2009, Heng 2013, Ko 2015 
 
Study patient prognosis will be evaluated using the International Metastatic Renal Cell 
Carcinoma Database Consortium (IMDC) model. The IMDC model was derived from 
multicenter data from the United States and Canada on 645  patients with no prior  antiangiogenic 
therapy (Heng 2009), and was validated in large studies of patients from multiple international 
centers in both first -line antiangiogenic targe ted therapy and second -line targeted therapy (with 
or without prior immunotherapy ; Heng 2013 and Ko 2015). In the setting of second -line targeted 
therapy for metastatic RCC, median overall survival was 35  mo in the favorable risk group 
(0 risk factors), 16.6  mo in the intermediate risk group (1 -2 risk factors), and 5.4  mo in the poor 
risk group (3 -6 risk factors ; Ko 2015). 
 
Worksheet for Determination of Prognostic Score in Previously Treated Patients  
Enter the patient‚Äôs  assessment value in the Patient Value Column. If the patient value meets the 
criteria then enter ‚Äú1‚Äù. To obtain the patient‚Äôs prognostic score, add up all the ‚Äú1‚Äù entered in 
last column.  The patient‚Äôs risk group is defined in the table below using the pat ient‚Äôs IMDC 
prognostic score.  
 
Parameter  Risk Factor  Criteria Value  Patient 
Value If Patient Value 
meets criteria, enter 
1 
Time from 
diagnosis to 
initiation of 
systemic therapy  Shorter time from diagnosis 
to systemic treatment for 
metastatic disease  < 1 year   
KPS Low performance status  ÀÇ 80%   
Hemoglobin  Low hemoglobin (anemia)  Males: < LLN 
Females: < LLN    
Corrected calcium  High calcium 
(hypercalcemia)  > ULN   
Neutrophil  High neutrophil count 
(neutrophilia)  >ULN   
Platelets High platelet count 
(thrombocytosis)  >ULN   
Sum total (IMDC Prognostic Score) :  
KPS, Karnofsky performance status; LLN, lower limit of normal; ULN, upper limit of normal.  
Note: ULN and LLN lab results are according to institution/local lab reference ranges  
 
Use IMDC Prognostic Score to identify patient‚Äôs risk group in the table below.  
 
Risk Group Based on IMDC Prognostic Score  
 
IMDC Risk Group  IMDC Prognostic Score  
Favorable Risk  0 
Intermediate Risk  1-2 
Poor Risk  3-6 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  86  ATTACHMENT 4: KARNOF SKY PERFORMANCE STAT US SCALE 
Percent Description  
100 Normal; no complaints; no evidence of disease.  
90 Able to carry on normal activity; minor signs or symptoms of disease.  
80 Normal activity with effort; some signs or symptoms of disease.  
70 Cares for self; unable to carry on normal activity or to do active work.  
60 Requires occasional assistance, but is able to care for most of their personal 
needs. 
50 Requires considerable assistance and frequent medical care.  
40 Disabled; requires special care and assistance.  
30 Severely disabled; hospital admission is indicated although death not 
imminent.  
20 Very sick; hospital admission necessary; active supportive treatment 
necessary.  
10 Moribund, fatal processes progressing rapidly.  
0 Dead 
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  87  ATTACHMENT 5: RECIST CRITERIA VERSION 1.1  
(Adapted from  Eisenhauer  2009) 
Sponsor‚Äôs Note s: CB-839 may affect glucose metabolism in both normal and tumor tissues. 
Preclinical data suggest that  glucose uptake may increase with glutaminase inhibition in sensitive 
tissues, reflecting the pharmacodynamics  effects of CB -839. False positive interpretations of 
progressive disease with FDG -PET scans may occur. Therefore, all FDG -PET findings 
suggestive of progressive disease should be confirmed by dedicated anatomic imaging (CT or 
MRI) for this study.   
Measurability of Tumor at Baseline  
Definitions  
At baseline, tumor lesions  will be categorized measur able or non -measurable as follows.  
Measurable tumor lesions  
Tumor lesions must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:   
ÔÇ∑ 10 mm by CT scan (CT scan slice thickn ess no greater than 5 mm)  
ÔÇ∑ 10 mm by caliper measurement (lesions which cannot be accurately measured with 
calipers should be recorded as non -measurable)  
ÔÇ∑ 20 mm by chest X -ray 
Malignant lymph nodes:  To be considered pathologically enlarged and measurable, a l ymph 
node must be  ÔÇ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness no 
greater than 5 mm).  At baseline and in follow -up, only the short axis will be measured and 
followed.  See also section below on ‚ÄòBaseline documentation of target an d non-target lesions‚Äô 
for information on lymph node measurement.  
Non-measurable tumor lesions  
Non-measurable tumor lesions encompass small lesions (longest diameter <10 mm or 
pathological lymph nodes with  ÔÇ≥ 10 to < 15 mm short axis) as well as truly non -measurable 
lesions. Lesions considered truly non -measurable include:  ascites, pleural or pericardial effusion, 
inflammatory breast disease, lymphangitic involvement of skin or lung, peritoneal spread, 
abdominal masses/abdominal  organomegaly identified by physical exam that is not measurable 
by reproducible imaging techniques.  
 
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  88  Special considerations regarding lesion measurability  
Bone lesions, cystic lesions, and lesions previously treated with local thera py require particular 
comment:  
Bone lesions:  
ÔÇ∑ Bone scan, PET scan or plain films are not considered adequate imaging techniques to 
measure bone lesions.  However, these techniques can be used to confirm the presence or 
disappearance of bone lesions.  
ÔÇ∑ Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components , that can be evaluated by cross sectional imaging techniques such as CT or 
MRI can be considered as measurable lesions if the soft tissue component meets the 
definition of  measurability described above.  
ÔÇ∑ Blastic bone lesio ns are non -measurable.  
Cystic lesions:  
ÔÇ∑ Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non -measurable) since they are, 
by definition, simple cysts . 
ÔÇ∑ ‚ÄòCystic lesions‚Äô thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above.  However, if non -
cystic lesions are present in the same patient, these are preferred for selection as targ et 
lesions. 
Lesions with prior local treatment:  
ÔÇ∑ Tumor lesions situated in a previously irradiated area, or in an area patiented to other 
loco-regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesi on. For this protocol, these tumor lesions will be 
considered non -measurable lesions.  
Specifications by methods of measurements  
Measurement of lesions  
All measurements should be recorded in metric notation, using calipers if clinically assessed.  All 
baseline evaluations should be performed as close as possible to the treatment start and never 
more than 4 weeks before the beginning of the treatment.  
Method of assessment  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  89  The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow -up. Imaging based evaluation should 
always be done rather than clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam.  
Clinical lesions : Clinical lesions will only be considered measurable when they are superficial 
and ÔÇ≥ 10 mm diameter as assessed using calipers (e.g., skin nodules).  For the case of skin 
lesions, documentation by color photography including a ruler to estimate the size of the lesion is 
suggested.  As noted above, when lesions can be evaluated by both clinical exam and imaging, 
imaging evaluation should be undertaken since it is more objective and may also be reviewed at 
the end of the study.  
CT, MRI: CT is the best currently available and reproducible method to measure lesions selected 
for response assessment.  This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm or less.  When CT scans have slice thickness 
greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  
MRI is also acceptable in certain situations (e.g., for body scans).  
If prior to enrol lment it is known that a patient is not able to undergo CT scans with IV contra st 
due to allergy or renal insufficiency, the decision as to whether a non -contrast CT or MRI (with 
or without IV contrast) will be used to evaluate the patient at baseline and follow -up, should be 
guided by the tumor type under investigation and the anato mic location of the disease  (Note:  see 
Section 10.6.9 for protocol -specific requirements; contrast -enhanced MRI of the abdomen and 
pelvis along with  non-contrast CT of the chest is strongly recommended if CT contrast is 
contraindicated ). For patients who develop contraindications to contrast after baseline contrast 
CT is done, the decision as to whether non -contrast CT or MRI (enhanced or non -enhanced ) will 
be performed should also be based on the tumor type, anatomic location of the disease and 
should be optimized to allow for comparison to the prior studies if possible.  Each case should be 
discussed with the radiologist to determine if substitution o f these other approaches is possible 
and, if not, the patient should be considered not evaluable from that point forward . 
Cytology, histology : These techniques can be used to differentiate between PR and CR in rare 
cases if required by protocol (for exampl e, residual lesions in tumor types such as germ cell 
tumors, where known residual benign tumors can remain).  When effusions are known to be a 
potential adverse effect of treatment (e.g., with certain taxane compounds or angiogenesis 
inhibitors), the cytolo gical confirmation of the neoplastic origin of any effusion that appears or 
worsens during treatment can be considered if the measurable tumor has met criteria for response 
or stable disease in order to differentiate between response (or stable di sease) and progressive 
disease. 
Tumor response evaluation  
Assessment of overall tumor burden and measurable disease  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  90  To assess objective response or future progression, it is necessary to estimate the overall tumor 
burden at baseline and use this as a comparator for  subsequent measurements.  Only patients with 
measurable disease at baseline should be included in protocols where objective tumor response is 
the primary endpoint.  Measurable disease is defined by the presence of at least one measurable 
lesion.  
Baseline documentation of ‚Äòtarget‚Äô and ‚Äònon -target‚Äô lesions  
When more than one measurable lesion is present at baseline all lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) representative of all inv olved organs 
should be identified as target lesions and will be recorded and measured at baseline.  
This means in instances where patients have only one or two organ sites involved a maximum of 
two (one site) and four lesions (two sites), respectively, will  be recorded.  Other lesions in that 
organ will be recorded as non -measurable lesions (even if size is greater than 10 mm by CT 
scan). 
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all  involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements . It may be the case that, on occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstance the next largest l esion which 
can be measured reproducibly should be selected.  
Lymph nodes  merit special mention since they are normal anatomical structures which may be 
visible by imaging even if not involved by tumor.  Pathological nodes which are defined as 
measurable and  may be identified as target lesions must meet the criterion of a short axis of 
ÔÇ≥15 mm by CT scan.  Only the short axis of these nodes will contribute to the baseline sum.  The 
short axis of the node is the diameter normally used by radiologists to judge if a node is involved 
by solid tumor.  Nodal size is normally reported as two dimensions in the plane in which the 
image is obtained (for CT scan this is almost always the axial plane; for MRI the plane of 
acquisition may be axial, saggital or coronal).  The smaller of these measures is the short axis. 
For example, an abdominal node which is reported as being 20 mm x 30 mm has a short axis of 
20 mm and qualifies as a malignant, measurable node.  In this example, 20 mm should be 
recorded as the node measurement.  All other pathological nodes (those with short axis ÔÇ≥ 10 mm 
but < 15 mm) should be considered non -target lesions.  Nodes that have a short axis <  10 mm are 
considered non -pathological and shou ld not be recorded or followed.  
A sum of the diameters  (longest fo r non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters . If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum.  The basel ine 
sum diameters will be used as reference to further characterize any objective tumor regression in 
the measu rable dimension of the disease.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  91  All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions and should also be recorded at baseline.  Measurements are not required and 
these lesions should be followed as ‚Äòpresent‚Äô, ‚Äòabsent‚Äô, or in rare cases ‚Äòunequivocal 
progression.‚Äô  In addition, it is possible to record multiple non -target lesions involving  the same 
organ as a single item on the case report form (e.g., ‚Äòmultiple enlarged pelvic lymph nodes‚Äô o r 
‚Äòmultiple liver metastases‚Äô).  
Response criteria  
This section provides the definitions of the criteria used to determine objective tumor response 
for target lesions.  
Evaluation of target lesions  
ÔÇ∑ Complete Response (CR) : Disappearance of all target lesions.  Any pathological lymph 
nodes (whether target or non -target) must have reduction in short axis to <  10 mm. 
ÔÇ∑ Partial Response (PR) : At least a 30% decrease in the sum of diameters of target lesions, 
taking as refere nce the baseline sum diameters.  
ÔÇ∑ Progressive Disease (PD) : At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes th e baseline sum if 
that is the smallest on study).  In addition to the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm.  (Note: the appearance of one or 
more new lesions is also considered progression).  
ÔÇ∑ Stable Dis ease (SD) : Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum diameters whil e on study.  
Special notes on the assessment of target lesions  
Lymph nodes : Lymph nodes identified as tar get lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline examination), 
even if the nodes regress to below 10 mm on study.  This means that when lymph nodes are 
included as target lesion s, the ‚Äòsum‚Äô of lesions may not be zero even if complete response criteria 
are met, since a normal lymph node is defined as having a short axis of <  10 mm. Case report 
forms or other data collection methods may therefore be designed to have target nodal le sions 
recorded in a separate section where, in order to qualify for CR, each node must achieve a short 
axis < 10 mm. For PR, SD , and PD, the actual short axis measurement of the nodes is to be 
included in the sum of target lesions.  
Target lesions  that become ‚Äòtoo small to measure‚Äô : While on study, all lesions (nodal and non -
nodal) recorded at baseline should have their actual measurements recorded at each subsequent 
evaluation, even when very small (e.g., 2 mm).  However, sometimes lesions or lymph nodes 
which are recorded as target lesions at baseline become so faint on CT scan that the radiologist 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  92  may not feel comfortable assigning an exact measure and may report them as being ‚Äòtoo small to 
measure‚Äô.  When this occurs it is important that a value be recorded  on the case report form:  
ÔÇ∑ If it is the opinion of the radiologist that the lesion has likely disappeared, the 
measurement should be recorded as 0 mm.  If the lesion is believed to be present and 
is faintly seen but too small to measure, a default value of 5  mm should be assigned 
and BML (below measurable limit) should be ticked (Note:  It is less likely that this 
rule will be used for lymph nodes since they usually have a definable size when 
normal and are frequently surrounded by fat such as in the retroperi toneum; however, 
if a lymph node is believed to be present and is faintly seen but too small to measure, 
a default value of 5 mm should be assigned in this circumstance as well and BML 
should also be ticked).  
This default value is derived from the 5 mm CT slice thickness (but should not be changed with 
varying CT slice thickness).  The measurement of these lesions is potentially non -reproducible, 
therefore providing this default value will prevent false responses or progressions based upon 
measurement error.  
To reiterate, however, if the radiologist is able to provide an actual measure, that should be 
recorded, even if it is below 5 mm and in that case BML should not be ticked.  (BML is 
equivalent to a less than sign <)  
Lesions that split or coalesce on treatment : When non-nodal lesions ‚Äòfragment‚Äô, the longest 
diameters of the fragmented portions should be added together to calculate the target lesion sum. 
Similarly, as lesions coalesce, a plane between them may be maintained that would aid in 
obtaining m aximal diameter measurements of each individual lesion.  If the lesions have truly 
coalesced such that they are no longer separable, the vector of the longest diameter in this 
instance should be the maximal longest diameter for the ‚Äòcoalesced lesion‚Äô.  
Evaluation of non -target lesions  
This section provides the definitions of the criteria used to determine the tumor response for the 
group of non -target lesions.  While some non -target lesions may actually be measurable, they 
need not be measured and instead shou ld be assessed only qualitatively at the time po ints 
specified in the protocol.  
Complete Response (CR) : Disappearance of all non -target lesions and normalization of tumor 
marker level.  All lymph nodes must be non -pathological in size (<  10 mm short axis).  
Non-CR/Non-PD: Persistence of one or more non -target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.  
Progressive Disease (PD) : Unequivocal progression of existing non -target lesions. (Note:  the 
appearance of one or more new lesi ons is also considered progression).  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  93  Special notes on assessment of progression of non -target disease  
The concept of progression of non -target disease requires addi tional explanation as follows:  
When the patient also has measurable disease : In this setting , to achieve ‚Äòunequivocal 
progression‚Äô on the basis of the non -target disease, there must be an overall level of 
substantial worsening in non -target disease in a magnitude that, even in presence of SD or 
PR in target disease, the overall tumor burden has i ncreased sufficiently to merit 
discontinuation of therapy.  A modest ‚Äòincrease‚Äô in the size of one or more non -target lesions is 
usually not sufficient to qualify for unequivocal progression status. The designation of overall 
progression solely on the basis  of change in non -target disease in the face of SD or PR of target 
disease will therefore be extremely rare.  
New lesions  
The appearance of new malignant lesions denotes disease progression; therefore, some 
comments on detection of new lesions are important . There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal:  i.e., not attributable to differences in scanning technique, change in imaging 
modality or findings thought to represent something other than tumor (for example, some ‚Äònew‚Äô 
bone lesions may be simply healing or flare of pre -existing lesions).  This is particularly 
important when the patient‚Äôs baseline lesions show partial or complete response.  For example, 
necrosis of a liver lesion may be reported on a CT scan report as a ‚Äònew‚Äô cystic lesion, which it is 
not. 
A lesion identified on a follow -up study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progre ssion. An example of this is 
the patient who has visceral disease at baseline and while on study has a brain CT or MRI 
ordered which reveals metastases.  The patient‚Äôs brain metastases are considered to be evidence 
of PD even if he/she did not have brain im aging at baseline.  
If a new lesion is equivocal, for example because of its small size, continued therapy and follow -
up evaluation will clarify if it represents truly new disease.  If repeat scans confirm there is 
definitely a new lesion, then progression should be declared using the date of the initial scan.  
(18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG -PET) For the purposes of 
this study, progressive disease should not  be made solely on FDG -PET findings because the 
mechanism of the st udy drug, CB-839, may affect glucose metabolism in both normal and tumor 
tissues. All FDG-PET findings suggestive of progressive disease should be confirmed by  
dedicated anatomic imaging ( CT or MRI). The following modifications to RECIST v1.1.  will be 
applied to t his study:  
ÔÇ∑ Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of 
PD based on a new lesion.  *Confirmation of  the new lesion  by CT or MRI scan is 
required per protocol.  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  94  ÔÇ∑ No FDG-PET at baseline and a positive FDG -PET at follow -up: 
o If the positive FDG -PET at follow -up corresponds to a new sign of disease 
confirmed by CT, this is PD  
o If the positive FDG -PET at follow -up is not confirmed as a new site of disease 
on CT, additional follow -up CT scans are needed to determine if there is truly  
progression occurring at that site (if so, the date of PD will be the date of the 
initial abnormal *CT scan). 
o If the positive FDG -PET at follow -up corresponds to a pre -existing site of 
disease on CT that is not progressing on the basis of the anatomic ima ges, this 
is not PD.  
*reflects study -specific modification to RECIST v.1.1  
Time point response  
It is assumed that at each protocol specified time point, a response assessment occurs.  Table A 
provides a summary of the overall resp onse status calculation at each time point for patients who 
have measurable disease at baseline.  
Missing assessments and not -evaluable designation  
When no imaging/measurement is done at all at a particular time point, the patient is not 
evaluable at that t ime point.  If only a subset of lesion measurements are made at an assessment, 
usually the case is also considered not evaluable at that time point, unless a convincing argument 
can be made that the contribution of the individual missing lesion(s) would not  change the 
assigned time point response.  This would be most like ly to happen in the case of PD.  For 
example, if a patient had a baseline sum of 50 mm with three measured lesions and at follow -up 
only two lesions were assessed, but those gave a sum of 80 mm, the patient will have achieved 
PD status, regardless of the cont ribution of the missing lesion.  
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
CONFIDENTIAL  95  Table A: Time Point Response:  Patients with Targets (+/ - Non-Target) Disease  
Target Lesions  Non-Target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/non-PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
Note: CR = complete response, PR = partial  response, SD = stable disease, PD = progressive disease, 
NE = inevaluable.  
 
Special notes on response assessment  
When nodal disease is included in the sum of target lesions and the nodes decrease to ‚Äònormal‚Äô 
size (< 10 mm), they may still have a measureme nt reported on scans.  This measurement should 
be recorded even though the nodes are normal in order not to overstate progression should it be 
based on increase in size of the nodes.  As noted earlier, this means that patients with CR may not 
have a total su m of ‚Äòzero‚Äô  on the case report form (CRF).  
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
‚Äòsymptomatic deterioration‚Äô.  Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response:  it is a reason for stopping study therapy.  The objective response status of 
such patien ts is to be determined by evaluation of target and non -target disease . 
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends upon this determination, it is recommended  
that the residual lesion be investigated (fine needle aspirate/biopsy) before assigning a status of 
complete response.   
For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes 
or necrosis in existing lesions), treatment may continue until the next scheduled assessment.  If at 
the next scheduled assessment, progression is confirmed, the date of progression should be the 
earlier date  when progression was sus pected
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
 
CONFIDENTIAL  96  ATTACHMENT 6: DRUG INTERACTIONS  
Drug Interactions with CB -839 
CYP2C9 Substrates with a 
narrow therapeutic index  Other CYP2C9 Substrates  
ÔÇ∑ S-Warfarin (anticoagulant)  
ÔÇ∑ Phenytoin (antiepileptic)  
 ÔÇ∑ NSAIDs (analgesic, antipyretic , anti-
inflammatory )  
o celecoxib  
o lornoxicam  
o diclofenac  
o ibuprofen   
o naproxen 
o ketoprofen  
o piroxicam  
o meloxicam  
o suprofen 
ÔÇ∑ fluvastatin  (statin) 
ÔÇ∑ sulfonylureas  (antidiabetic )  
o glipizide 
o glibenclamide  
o glimepiride  
o tolbutamide  
o glyburide  
ÔÇ∑ irbesartan losartan 
ÔÇ∑ sildenafil (in erectile dysfunction ) 
ÔÇ∑ terbinafine  (antifungal ) 
ÔÇ∑ amitriptyline ( tricyclic antidepressant ) 
ÔÇ∑ fluoxetine ( SSRI antidepressant)  
ÔÇ∑ nateglinide  (antidiabetic)  
ÔÇ∑ rosiglitazone  (antidiabetic ) 
ÔÇ∑ tamoxifen  (SERM) 
ÔÇ∑ torasemide  (loop diuretic ) ketamine 
*Narrow therapeutic index is defined as ‚Äú CYP substrates with narrow therapeutic range  refers 
to drugs whose exposure -response relationship indicates that small increases in their exposure 
levels by the concomitant use of CYP inhibitors may lead to serious safety concerns (e.g., 
Torsades de Pointes).‚Äù  
http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionsla
beling/ucm093664.htm  
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
 
CONFIDENTIAL  97  Drug Interactions with Cabozantinib  
CYP3A4 Inhibition on  Cabozantinib  
Administration of a strong CYP3A4 inhibitor, ketoconazole (400 mg daily for 27 days) to  
healthy patients increased single -dose plasma cabozantinib exposure (AUC 0-inf) by 38%. 
Concomitant use of cabozantinib with a strong CYP3A4 inhibitor increased the exposure of 
cabozantinib compared to the use of cabozantinib alone. Reduce the dosage of cabozantinib  if 
concomitant use with strong CYP3A4 inhibitors cannot be avoided.  
Examples include: boceprevir, clarithromycin, conivaptan, erythromycin, grapefruit juice, 
indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, 
ritonavir, saquinavir, telithromycin, verapamil, and voriconazole  
CYP3A4 Induction on Cabozantinib  
Administration of a strong CYP3A4 inducer , rifampin (600 mg daily for 31 days) to healthy  
patients decreased single -dose plasma cabozantinib exposure (AUC 0-inf) by 77%. Concomitant 
use of cabozantinib with a strong CYP3A4 inducer decreased  the exposure of cabozantinib 
compared to the use of caboz antinib alone. Increase the dosage of cabozantinib  if concomitant 
use with strong CYP3A4 inducers cannot be avoided.  
Examples include: rifampin, phenytoin, carbamazepine, phenobarbital, rifabutin, rifapentine, and 
St. John‚Äôs Wort    
 
  
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
 
CONFIDENTIAL  100  ATTACHMENT 8:  EUROQO L QUESTIONNAIRE ED -5D-5L (US ENG LISH SAMPLE 
VERSION)  
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
 
CONFIDENTIAL  101   
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
 
CONFIDENTIAL  102  ATTACHMENT 9: SUMMARY OF CHANGES  (AMENDMENT 3.0 VS. 2.0) 
Section Change Rationale  
4.0  Updated emergency contacts and 
SAE reporting contact  Result of staff changes  
5.0  Additional objectives for PK 
updated  Included PK analysis of cabozantinib, 
and the major CB -839 metabolite 
110826 using sparse PK sampling.  
The Population PK analysis will be the 
subject of a separate report. Clarified 
that the purpose of the PK analyses are 
to evaluate the relationship betw een 
drug and metabolite exposure and the 
efficacy and safety, as well as evaluate  
the possible effect of CB -839 on 
cabozantinib exposure  
8.1  Clarified inclusion criteria 3e  Removed creatinine  (typo) as 
described in the protocol clarification 
letter previously submitted to sites and 
IRBs/ECs  
9.4.1  Added phase 1 study CX -839-001 
for the CB -839 + cabozantinib 
data Clarified that the CB -839 + 
cabozantinib data was based on the 
phase 1 study CX -839-001 
9.4.2  Added phase 1 study CX -839-001 
for the efficacy of CB -839 plus 
cabozantinib data  Clarified that the efficacy data of CB -
839 + cabozantinib was based on the 
phase 1 study CX -839-001 
10.3  Added instructions for patients 
who discontinue either CB -
839/placebo or cabozantinib  Added language that patients should 
continue with their scheduled study 
visits and procedures per protocol if 
they discontinue either CB -
839/placebo or cabozantinib for any 
reason such as an AE or surgery  
10.4 Clarified language for survival 
follow-up  Clarified that patients will be contacted 
every 3 months for the first 12 months 
and every 6 months thereafter after 
discontinuing CB -839/placebo and 
cabozantinib for survival follow -up 
10.6.11  Included 110826 (major 
metabolite of CB -839) and 
cabozantinib for PK analysis  Updated due to revised additional 
objectives for PK  
15.1  Updated other reportable 
information language  Clarified that other reportable 
information should be recorded, 
reported, and followed up within the 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
CB-839 Protocol CX -839-008 
 09 April 2020 Amendment 3.0 
 
 
CONFIDENTIAL  103  same expedited timelines as for an 
SAE 
15.1  Updated overdose and abuse 
definition  Added instructions on how to record 
and report overdoses and abuses 
depending on whether they are an AE 
or SAE 
15.2 Updated safety follow -up 
language Clarified that patients will be followed 
for AEs or SAEs from initiation of 
study treatment through at least 28 
days after the last dose of all study 
treatments (CB -839/placebo and 
cabozantinib) or until initiation of a 
new anticancer therapy (if earlier)  
Attachment 1  Updated window for end of 
treatment/follow up visit  Included +7 day window per protocol 
clarification letter previously submitted 
to sites and IRBs/ECs  
Attachment 1  Updated footnote 4  Revised language to match language in 
section 15.2  
Attachment 1  Updated footnote 17  Clarified that patients will be contacted 
every 3 months for the first 12 months 
and every 6 months thereafter after 
discontinuing CB -839/placebo and 
cabozantinib for survival follow -up 
Attachment 2  Added footnote 2 to serum 
chemistry panel for blood urea 
nitrogen Updated per protocol clarification 
letter previously submitted to sites and 
IRBs/ECs. Blood BUN and blood urea 
results will be accepted for blood urea 
nitrogen tests.  
 
 
 
 
CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
Signature Page for VV-TMF-62771 v1.0
Signature Page for VV-TMF-62771 v1.0Reason for signing: Approved Name: 
Role: C opment
Date of signature: 10-Apr-2020 19:42:50 GMT+0000
Reason for signing: Approved Name: 
Role: C perations
Date of signature: 10-Apr-2020 19:45:58 GMT+0000
Reason for signing: Approved Name: 
Role: B
Date of signature: 10-Apr-2020 20:10:23 GMT+0000
Reason for signing: Approved Name: 
Role: C ent
Date of signature: 10-Apr-2020 20:52:48 GMT+0000
Reason for signing: Approved Name: 
Role: R irs
Date of signature: 11-Apr-2020 00:01:43 GMT+0000CX-839-008 Protocol Amendment 09Apr2020 | eTMF Version 1.0 | VV-TMF-62771
